US20100129372A1 - Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia - Google Patents
Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia Download PDFInfo
- Publication number
- US20100129372A1 US20100129372A1 US12/550,605 US55060509A US2010129372A1 US 20100129372 A1 US20100129372 A1 US 20100129372A1 US 55060509 A US55060509 A US 55060509A US 2010129372 A1 US2010129372 A1 US 2010129372A1
- Authority
- US
- United States
- Prior art keywords
- pacap
- platelet
- vip
- thrombocytopenia
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010043554 thrombocytopenia Diseases 0.000 title claims abstract description 47
- 230000011664 signaling Effects 0.000 title claims abstract description 32
- 238000011282 treatment Methods 0.000 title claims abstract description 28
- 230000002265 prevention Effects 0.000 title abstract description 15
- 230000005764 inhibitory process Effects 0.000 title description 20
- 101150060255 MZB1 gene Proteins 0.000 title 1
- 101100462550 Mus musculus Adcyap1 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 claims abstract description 27
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 claims abstract description 6
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 claims abstract description 6
- 102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 claims description 33
- 101710137655 Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 26
- 238000002512 chemotherapy Methods 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 239000012678 infectious agent Substances 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000001772 blood platelet Anatomy 0.000 abstract description 134
- 238000004519 manufacturing process Methods 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 17
- 239000005557 antagonist Substances 0.000 abstract description 12
- 230000003247 decreasing effect Effects 0.000 abstract description 5
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 58
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 58
- 241000699670 Mus sp. Species 0.000 description 42
- 102000005962 receptors Human genes 0.000 description 40
- 108020003175 receptors Proteins 0.000 description 40
- 102000014743 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Human genes 0.000 description 34
- 108010064032 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Proteins 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 28
- 102000008186 Collagen Human genes 0.000 description 26
- 108010035532 Collagen Proteins 0.000 description 26
- 229920001436 collagen Polymers 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- UFTCZKMBJOPXDM-UHFFFAOYSA-N 4-[[2-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[6-amino-1-[[5-amino-1-[[1-[[1-[[1-[[6-amino-1-[[6-amino-1-[[1-[[1-[[1-[[1-[[1-[[1-[[2-[[6-amino-1-[[1-[[1-[[6-amino-1-[[5-amino-1-[[1-[[1-[[6-amino-1-[[4-amino-1-[(1,6-diamino-1-oxohexan-2-yl)amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-[[2-[[2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoic acid Chemical compound CCC(C)C(NC(=O)CNC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(N)Cc1c[nH]cn1)C(=O)NC(Cc1ccccc1)C(=O)NC(C(C)O)C(=O)NC(CC(O)=O)C(=O)NC(CO)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CO)C(=O)NC(CCCNC(N)=N)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCC(N)=O)C(=O)NC(CCSC)C(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CCCCN)C(=O)NC(CCC(N)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NC(CCCCN)C(N)=O UFTCZKMBJOPXDM-UHFFFAOYSA-N 0.000 description 21
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 21
- 230000001965 increasing effect Effects 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- 208000007536 Thrombosis Diseases 0.000 description 19
- 208000032843 Hemorrhage Diseases 0.000 description 18
- 208000034158 bleeding Diseases 0.000 description 18
- 231100000319 bleeding Toxicity 0.000 description 18
- 230000000740 bleeding effect Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000012634 fragment Substances 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 17
- 239000000556 agonist Substances 0.000 description 15
- 210000002950 fibroblast Anatomy 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 230000002776 aggregation Effects 0.000 description 13
- 238000004220 aggregation Methods 0.000 description 13
- 102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 description 12
- 102000030621 adenylate cyclase Human genes 0.000 description 12
- 108060000200 adenylate cyclase Proteins 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000994 Catalytic RNA Proteins 0.000 description 11
- 102000053642 Catalytic RNA Human genes 0.000 description 11
- 101000666868 Homo sapiens Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 description 11
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108091092562 ribozyme Proteins 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000023597 hemostasis Effects 0.000 description 10
- 229960002240 iloprost Drugs 0.000 description 10
- 210000003593 megakaryocyte Anatomy 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 108010011014 pituitary adenylate-cyclase-activating-peptide (6-38) Proteins 0.000 description 10
- 210000004623 platelet-rich plasma Anatomy 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108020005544 Antisense RNA Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000003184 complementary RNA Substances 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 239000000018 receptor agonist Substances 0.000 description 6
- 229940044601 receptor agonist Drugs 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 108020004491 Antisense DNA Proteins 0.000 description 5
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 5
- 208000037280 Trisomy Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003816 antisense DNA Substances 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 208000030454 monosomy Diseases 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000005945 translocation Effects 0.000 description 5
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 210000003567 ascitic fluid Anatomy 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- -1 cyclic lactam Chemical class 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- DRLDAGKWYRHQAE-RLUUKXCJSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1,4-diamino-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]pentanediamide Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 DRLDAGKWYRHQAE-RLUUKXCJSA-N 0.000 description 3
- SIOKKMOWMDCVKB-RGBLINGASA-N (3S)-4-[[2-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[[2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O SIOKKMOWMDCVKB-RGBLINGASA-N 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 101000735539 Homo sapiens Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 3
- 101000666856 Homo sapiens Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 208000036626 Mental retardation Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108010025501 PG 97-269 Proteins 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 208000036623 Severe mental retardation Diseases 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 229960004676 antithrombotic agent Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229960002101 secretin Drugs 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000003582 thrombocytopenic effect Effects 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 229940038773 trisodium citrate Drugs 0.000 description 3
- 108010043936 vasoactive intestinal peptide (10-28) Proteins 0.000 description 3
- 101150084623 vip gene Proteins 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101000735538 Mus musculus Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 102100035733 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 102100037790 VIP peptides Human genes 0.000 description 2
- 102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 description 2
- 108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- IAWMQYIXAKXMGI-GIJPRFPSSA-N chembl501240 Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)C1=CN=CN1 IAWMQYIXAKXMGI-GIJPRFPSSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 210000003372 endocrine gland Anatomy 0.000 description 2
- 230000002616 endonucleolytic effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 102000056275 human VIPR1 Human genes 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940074383 interleukin-11 Drugs 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- BGZYREVJBMQLGS-ONKNJJKASA-N pacap 6-38 Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)[C@@H](C)O)C1=CC=C(O)C=C1 BGZYREVJBMQLGS-ONKNJJKASA-N 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003815 prostacyclins Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000004739 secretory vesicle Anatomy 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000035921 thrombopoiesis Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- MTFZMVUYAILXSB-UHFFFAOYSA-N 2,6,10,10-tetramethylpentadecane Chemical compound CCCCCC(C)(C)CCCC(C)CCCC(C)C MTFZMVUYAILXSB-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 108091027075 5S-rRNA precursor Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100030802 Beta-2-glycoprotein 1 Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010011498 Cryptorchism Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 201000006360 Edwards syndrome Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 238000011771 FVB mouse Methods 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
- 101001128500 Homo sapiens Marginal zone B- and B1-cell-specific protein Proteins 0.000 description 1
- 101001071312 Homo sapiens Platelet glycoprotein IX Proteins 0.000 description 1
- 101000642431 Homo sapiens Pre-mRNA-splicing factor SPF27 Proteins 0.000 description 1
- 101000805490 Homo sapiens VIP peptides Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- IFQSXNOEEPCSLW-DKWTVANSSA-N L-cysteine hydrochloride Chemical compound Cl.SC[C@H](N)C(O)=O IFQSXNOEEPCSLW-DKWTVANSSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100198353 Mus musculus Rnasel gene Proteins 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- VXOKDLACQICQFA-UHFFFAOYSA-N N-Desethylamiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCNCC)C(I)=C1 VXOKDLACQICQFA-UHFFFAOYSA-N 0.000 description 1
- 101001068640 Nicotiana tabacum Basic form of pathogenesis-related protein 1 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102100036851 Platelet glycoprotein IX Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000590419 Polygonia interrogationis Species 0.000 description 1
- 102100036347 Pre-mRNA-splicing factor SPF27 Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 101710145796 Staphylokinase Proteins 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 101710128740 VIP peptides Proteins 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010023562 beta 2-Glycoprotein I Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000036279 complete trisomy 18 Diseases 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 201000000160 cryptorchidism Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000000001 effect on platelet aggregation Effects 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000055955 human ADCYAP1 Human genes 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 201000004108 hypersplenism Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000005074 megakaryoblast Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 108010068982 microplasmin Proteins 0.000 description 1
- 108010015052 miniplasmin Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000011234 negative regulation of signal transduction Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- RZGBUJXSKLDAFE-QYHUGZLJSA-N pacap 1-27 Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)C1=CN=CN1 RZGBUJXSKLDAFE-QYHUGZLJSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 238000010577 post-coronary angioplasty Methods 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 201000009225 splenic sequestration Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229950000329 thiouracil Drugs 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000003022 thrombocytopoietic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 206010053884 trisomy 18 Diseases 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2073—IL-11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
Definitions
- This invention relates to compounds useful in the control of the primary haemostasis and the modulation of platelet number, as well as methods of use of these compounds.
- the initial response to interruption of continuity of a blood vessel is defined as primary haemostasis.
- Platelets play a major role in the pathophysiology of primary haemostasis. The clinical importance of platelets first became obvious when thrombocytopenic patients, who later on were diagnosed as having immune mediated thrombocytopenia (ITP), had thrombocytopenic purpura. Platelets participate in haemostasis by sealing vascular injuries and by fostering the process of blood coagulation. Not only the number of the platelets is important (thrombocytopenia for whatever reason) but also their intrinsic function upon activation: change in platelet shape, adhesion, aggregation and secretion are prerequisites for normal haemostasis. Congenital or acquired disorders interfering with one of the platelet functions can lead to mild to even severe bleeding problems.
- Platelets also play a role in the development of arterial thrombosis. Disruption of the endothelial cell lining of the vessels exposes adhesive proteins within the subendothelial matrix, leading to platelet attachment. Thereafter, platelet spreading, as well as platelet secretion occurs. The secretion of the content of platelet granules can stimulate circulating platelets to acquire new adhesive properties. Finally, stimulated platelets interact with each other during platelet aggregation and a platelet-rich thrombus is formed, which can compromise the patency of blood vessels. Furthermore activated platelets accelerate the rate of activation of coagulation proteins. Phospholipids on the platelet surface facilitate thrombin generation and fibrin strand formation.
- Prevention and treatment of thrombosis are therefore based on administration of antiplatelet drugs, anticoagulants or thrombolytic therapy or combinations thereof.
- the pituitary Adenylyl Cyclase Activating Peptide (PACAP 1-38) is a 38-amino acid peptide that was first isolated from ovine hypothalamic extracts on the basis of its ability to stimulate cAMP formation in anterior pituitary cells [Miyata A. et al. (1989) Biochem Biophys Res Commun 164, 567-574; Vaudry D. et al. (2000) Pharm Rev 52, 269-324].
- PACAP is a member of the Vasoactive Intestinal Polypeptide (VIP)-glucagon-growth hormone releasing factor-secretin superfamily. Its role in biology is probably crucial, since the sequence of PACAP is highly conserved during the evolution from protochordate to mammals.
- PACAP-specific PACAP receptor coupled to different signal transduction systems
- PACAP PACAP-indifferent receptors
- VPAC1 and VPAC2 also referred to as VIPR1 and VIPR2
- VIPR1 and VIPR2 are primarily coupled to adenylyl cyclase.
- the invention relates to the use of an inhibitor of PACAP signalling for the manufacture of a medicament for the prevention or treatment of thrombocytopenia.
- the inhibitor of PACAP signalling can target expressed PACAP, expressed VIP or a receptor for PACAP.
- a receptor for PACAP can be the PACAP receptor (PACAPR), VPAC1 or VPAC2.
- the inhibitor can be an antagonist which interferes with PACAP, VIP or a PACAP receptor protein.
- the inhibitor can inhibit the transcription or translation of PACAP, VIP or a receptor for PACAP.
- Examples of inhibitors of transcription and translation include an antisense molecule, an RNAi, an aptamer, a small molecule, an antibody, a ribozyme, a transdominant receptor, and a tetrameric peptide.
- PACAP3 Specific compounds having an inhibitory effect on PACAP signalling include max.d.4 5, PACAP6-38, [4CI-D-Phe6, Leu17]VIP, VIP(10-28), cyclic lactam analogs of PACAP, [AcHis(1), D-Phe(2), Lys(15), Leu(17)]VIP(3-7)/GRF(8-27), PACAP receptor blocking Cyclic lactam PACAP analogs, N-terminal truncated or substituted VIP peptide PACAP receptor blockers, neutralising antibodies against VPAC(1), and neutralising aptamer against VPAC(1) receptor, [4CI-D-Phe6, Leu17]VIP, VIP(10-28).
- the invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising an inhibitor of PACAP signalling and an additional compound for enhancing megakaryocyte maturation such as thrombopoetin or Interleukin 11.
- the invention also relates to the use of pituitary adenylyl cyclase activating peptide (PACAP), its derivatives, mimetics, antibodies or inhibitors for modulating the primary haemostasis or thrombocytopoiesis or the use of agonists or antagonists of the platelet receptor, VPAC1, to modulate the primary haemostasis or thrombocytopoiesis.
- PACAP pituitary adenylyl cyclase activating peptide
- VPAC1 platelet receptor
- the present invention further relates to a method for prevention as a prophylactic and for the treatment of either thrombosis or bleeding based on administration of pituitary adenylyl cyclase activating peptide (PACAP) mimetics or inhibitors respectively.
- PACAP pituitary adenylyl cyclase activating peptide
- the present invention shows that human platelets express the VPAC1 receptor.
- the present invention also shows that PACAP has an important function in primary haemostasis: platelet number as well as platelet function are highly influenced by PACAP.
- the invention provides compositions and methods useful for activating thrombocytopoiesis in mammals, including humans.
- the invention applies to human and veterinary applications.
- the inventive composition and method have been shown to be especially effective in treating platelet hypofunction.
- the present invention finds utility in e.g., radiation treatment or chemotherapeutic treatment or sickness caused by radiation accidents, where prevention or treatment of thrombocytopenia, anemia and neutropenia is a significant concern.
- the depletion of hematopoietic precursors in the bone marrow associated with chemotherapy and irradiation results in hemorrhagic and infectious complications. Severe suppression of the hematopoietic system is a major factor in limiting chemotherapy use and dose escalation.
- Compounds useful for exercising the thrombocytopoietic treatment or the manufacturing of a medicament for platelet hypofunction of present invention are thus compounds that inhibit the activity of PACAP or VIP and more specifically that antagonise the platelet receptor for PACAP.
- FIG. 1 Family presentation. Squares, male; circles, female; filled symbols, affected individuals; open symbols, unaffected individuals.
- Patient (VI:1) is the propositus. Black filled symbols represent members with severe mental retardation and a partial trisomy 18p and monosomy 20p, striped boxes represent members with borderline IQ and the balanced translocation t(18;20) (p21;p13) while question marks stand for members with unexplained mental retardation but unknown karyotype.
- FIG. 2 Platelet aggregation and adenylyl cyclase activity. Measurements of cAMP levels under basal conditions ( 2 A) performed in duplicate (left panel) or after stimulation with Iloprost (1 ng/ml) ( 2 B) for various time intervals (right panel) in platelets from VI:1 (v) or an unrelated control (CrI)(X). Measurements of cAMP levels under basal conditions performed in duplicate (left panel) or after stimulation with isoproterenol (1 ⁇ M) for various time intervals (right panel) in fibroblasts from VI:1, a patient with trisomy 18 ( ⁇ ) or an unrelated control (CrI) (X). All cAMP measurements were performed in the presence of the phosphodiesterase inhibitor IBMX (400 ⁇ M).
- FIG. 3 PACAP detection in fibroblasts and plasma.
- 3 A Semi-quantitative RT-PCR using 20 cycles and 17 showed PACAP(1-38) overexpression in fibroblasts from patient VI:1 compared with two controls. ⁇ -actin is the internal control.
- 3 B PACAP mRNA detection in fibroblasts, megakaryocytic cell lines DAMI, MEG-01 and K562, and platelets was performed by RT-PCR.
- 3 C Immunoblot analysis of the VPAC1 receptor (58 kDa) in platelets from two unrelated controls and patient VI:1.
- 3 F Collagen induced aggregation of control platelets in plasma from a control or from patient IV:1 (two experiments shown).
- FIG. 4 Role of PACAP(6-38) in platelet aggregation.
- 4 A Right panel: the collagen-induced (5 mg/ml) platelet aggregation in hirudinized PRP from 2 WT and two PACAP-Tg mice are shown.
- 4 B The left panel shows the dose-dependent stimulation by PACAP(6-38) of the collagen-induced (0.2 ⁇ g/ml) aggregation of human platelets; representative tracings of five separate experiments.
- PACAP (6-38) The effect of PACAP (6-38) on the collagen-induced platelet aggregation (2 microgramg/ml) for patient VI:1 is illustrated in the right panel.
- 4 C The platelet aggregation inhibition test with collagen (2 ⁇ g/ml) and different concentrations of Iloprost (ng/ml) as indicated in the absence (left panels) and presence (right panels) of PACAP(6-38) for a control (upper panels) or patient VI:1 (lower panels).
- FIG. 5 Effect of anti-PACAP antibodies in mice. Platelet aggregation was performed in PRP pooled from five mice of each group with 250 ⁇ 10 3 plt/ ⁇ l.
- 5 A The platelet aggregation inhibition test with collagen (2 ⁇ g/ml) and preincubation of Iloprost (10 ng/ml) for mice injected with the indicated antibodies.
- 5 B Platelet aggregation induced with a low concentration of collagen (0.2 ⁇ g/ml) for mice injected with the indicated antibodies.
- 5 C Stimulatory effect of a polyclonal anti-PACAP antibody (10 ⁇ g/ml) on collagen-induced (0.35 ⁇ g/ml) platelet aggregation.
- 5 D FACS analysis showed a reduced expression of glycoprotein IX (CD42a) in platelets from patient VI:1 versus control platelets (left panel) and a reduced expression of glycoprotein IIIA (CD61) in the megakaryocytes of the PACAP overexpressing mice compared to cells of the control mice (right panel). These experiments were repeated twice with identical results.
- 5 E Electron micrograph of megakaryocyte progenitor cell. Specific granules are seen as well as a dense core vesicle (arrow). A few endoplasmic reticulum cisternae are obvious. Original magnification: ⁇ 18.500.
- PACAP refers to Pituitary Adenylate Cyclase-Activating Polypeptide and refers to the mature and processed versions of the mature PACAP as PACAP(1-48) and more particularly to processed isoforms PACAP(1-38) HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2 [SEQ ID NO:1] and PACAP(1-27) HSDGIFTDSYSRYRKQMAVKKYLAAVL-NH2 [SEQ ID NO:2].
- PACAP refers to PACAP of vertebrates, including mammalian PACAP and human PACAP.
- VIP refers to Vasoactive Intestinal Peptide (VIP), a 28-amino acid peptide which exhibits a wide variety of biologic actions. Because VIP shows similarities to glucagon, secretin and gastric inhibitory peptide (GIP), it has been considered a member of the glucagon-secretin family.
- GIP gastric inhibitory peptide
- prepro-VIP The primary translation product of the mRNA encoding VIP has a molecular weight of 20 daltons.
- receptor for PACAP refers to a receptor which is bound and activated by PACAP including the PACAP receptor (PACAPR) [OMIM 102981] which is specific for PACAP but also to VPAC1 (VIPR1) [OMIM 192321] and VPAC2 (VIPR2) [OMIM 601970] receptors which bind both PACAP and VIP (Vasoactive Intestinal peptide).
- PACAP receptor PACAP receptor
- VPAC1 VPAC1
- VPAC2 VPAC2
- thrombocytopenia is any disorder in which the platelet level in the affected individual fall below a normal range of platelet numbers for that individual, due to disturbance in production distribution or destruction.
- normal blood platelet levels range from about 150.000 to 300.000 per microliter peripheral blood.
- a platelet level of 100.000 per microliter patients have no abnormal bleeding even with major surgery; with a platelet count of 50.000 to 100.000 per microliter, patients may bleed longer than normal with severe trauma; with a platelet count of 20.000 to 50.000 per microliter, bleeding occurs with minor trauma but spontaneous bleeding is unusual; with a platelet count of less than 20.000, patients may have spontaneous bleeding and when the platelet count is less than 10.000 per microliter, patients are at high risk for severe bleeding.
- Thrombocytopenia also refers to a decrease in platelet number in an individual when compared to the platelet number measured at a certain reference point in that individual.
- the decrease in platelet number in the individual can be a decrease in more than 20%, 30%, 40%, 60%, 80%, 90%, 95% or even more, compared to value at the reference point.
- a decrease in platelet number when compared to the platelet number measured at a certain reference point can in certain individuals be accompanied with changes in bleeding, while in other individuals a comparable decrease will not be accompanied with changes in bleeding.
- the reference point mentioned can be for instance the start of a therapy such as a radiation or chemotherapy.
- Thrombocytopenia includes infection-induced thrombocytopenia, treatment-induced thrombocytopenia and others.
- “Infection-induced thrombocytopenia” is a disorder characterised by a lowered level of platelets in peripheral blood, which is caused by an infectious agent such as a bacteria or virus.
- Treatment-induced thrombocytopenia is a disorder characterised by a lowered level of platelets in peripheral blood which is caused by therapeutic treatments such as gamma irradiation, therapeutic exposure to radiation, cytotoxic drugs, chemicals containing benzene or anthracene and even some commonly used drugs such as chloramphenicol, thiouracil, and barbiturate hypnotics.
- “Other types of thrombocytopenia” comprise disorders characterised by a low level of platelets in peripheral blood, which are caused by any mechanism other than infectious agents or therapeutic treatments causing thrombocytopenia.
- Factors causing this type of thrombocytopenia include, but are not limited to, rare bone marrow disorders such as congenital amegakaryocytic hypoplasia and thrombocytopenia with absent radii (TAR syndrome), an increase in spleen size, or splenomegaly, caused by portal hypertension, secondary to liver disease, or macrophage storage disorders such as Gauchers disease, autoimmune disorders such as idiopathic or immune thrombocytopenic purpura (ITP), vasculitis, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura (TTP), disseminated intravascular coagulation (DIC) and prosthetic cardiac valves. ITP is by far the most frequent type in this group of thrombocytopenias.
- a “subject having thrombocytopenia” is a subject having any type of thrombocytopenia and includes but is not limited to non-chemotherapeutic-induced thrombocytopenia, or chemotherapeutic-induced thrombocytopenia.
- a subject at risk of developing thrombocytopenia is a subject who has a high probability of acquiring or developing thrombocytopenia.
- a patient with a malignant tumour who is prescribed a chemotherapeutic treatment is at risk of developing treatment-induced thrombocytopenia and a subject who has an increased risk of exposure to infectious agents is at risk of developing infection-induced thrombocytopenia.
- PACAP signalling refers to the binding and activation of a receptor for PACAP. It thus relates to the binding of PACAP to the PACAC receptor, VPAC1 or VPAC2 r and subsequent activation. Moreover PACAP signalling also includes binding and activation of VPAC1 and VPAC2 by VIP. In a particular embodiment “PACAP signalling” relates to signalling via the VPAC1 receptor present on megakaryocytes in bone marrow.
- “Inhibition of PACAP signalling” refers to the inhibition of the binding of PACAP or VIP to a receptor for PACAP, which includes inhibition of the production and/or activity of the ligands PACAP and/or VIP (PACAP or VIP inhibition by PACAP and/or VIP inhibitors) and inhibition of the production or function of one or more receptors for PACAP or the binding of PACAP or VIP thereto (PACAP receptor inhibition), e.g. by antibodies, antagonists, soluble receptors, antisense etc, as detailed herein. These molecules are also generally referred to herein as ‘inhibitors of PACAP signalling’.
- anti-PACAP antibody or antibodies relates to an antibody or antibodies characterised as being specifically directed against PACAP, VIP or any functional derivative thereof, with said antibodies being preferably monoclonal antibodies or an antigen-binding fragment thereof, of the F(ab′) 2 , F(ab) or single chain Fv type, or any type of recombinant antibody or antibody fragment derived thereof.
- said antibody or fragment thereof is humanized or is in other ways appropriate for injection into the subject to be treated therewith.
- anti-PACAP Receptor antibody or antibodies relates to an antibody or antibodies characterised as being specifically directed against one or more of thereceptors for PACAP (PACAPR, VPAC1 and VPAC2) with said antibodies being preferably monoclonal antibodies; or an antigen-binding fragment thereof, of the F(ab′) 2 , F(ab) or single chain Fv type, or any type of recombinant antibody derived thereof.
- the monoclonal antibodies of the invention can, for instance, be produced by any hybridoma produced according to classical methods using splenic cells of an animal, particularly of a mouse or rat immunized against a receptor for PACAP, PACAP, VIP, a molecule involved in PACAP signalling, or any functional derivative thereof, and cells of a myeloma cell line, and can be selected by the ability of the hybridoma to produce the monoclonal antibodies recognizing a receptor for PACAP, PACAP, VIP, the molecule involved in PACAP signalling, or any functional derivative thereof which has been initially used for the immunization of the animals.
- the monoclonal anti-PACAP or antibodies against a receptor for PACAP may be humanized versions of the non-human monoclonal antibodies, made by means of recombinant DNA technology, departing from the mouse and/or human genomic DNA sequences coding for H and L chains or from cDNA clones coding for H and L chains.
- the monoclonal antibodies according to this embodiment of the invention may be human monoclonal antibodies.
- Such human monoclonal antibodies are prepared, for instance, by means of human peripheral blood lymphocytes (PBL) repopulation of severe combined immune deficiency (SCID) mice as described in PCT/EP99/03605 or by using transgenic non-human animals capable of producing human antibodies as described in U.S. Pat. No.
- fragments derived from these monoclonal antibodies such as Fab, F(ab)′2 and ssFv (“single chain variable fragment”), provided they have retained the original binding properties, form part of the present invention.
- Such fragments are commonly generated by, for instance, enzymatic digestion of the antibodies with papain, pepsin, or other proteases. It is well known to the person skilled in the art that monoclonal antibodies, or fragments thereof, can be modified for various uses.
- An appropriate label of the enzymatic, fluorescent, or radioactive type can label the antibodies involved in the invention.
- stimulation of PACAP signalling refers to the stimulation of a signal caused by the binding of PACAP, VIP or an agonist thereof to a receptor for PACAP which includes stimulation of the production or increase of the presence of the ligands PACAP and/or VIP, or agonists thereof or stimulation of the production or activity of one or more of a receptor for PACAP or the binding of PACAP or VIP thereto (PACAP receptor stimulation), e.g. by agonists, co-expression of PACAP or VIP-like molecules, etc, as detailed herein. These molecules are also generally referred to herein as ‘stimulators of PACAP signalling’.
- treatment refers to any process, action, application, therapy, or the like, wherein a subject or individual is subjected to medical aid with the object of improving or maintaining the mammal's condition, directly or indirectly.
- Subject, individual or patient refers to a mammal and includes a laboratory animal, pet, agriculture animal; examples include dogs, cats, horses, rodents (rats, mice, hamsters, guinea pigs), cattle, pigs, rabbits, goats, among others.
- a mammal also refers to monkeys and primates, including humans.
- the present invention relates to the modulation of platelet function and number through the inhibition of PACAP signalling.
- the present invention relates to the inhibition of PACAP signalling by targeting PACAP and/or VIP in a subject and to compounds useful therefore.
- PACAP and/or VIP inhibition in the peripheral blood of a subject.
- PACAP and/or VIP inhibitors include polyclonal or monoclonal antibodies or antibody fragments against PACAP or VIP.
- Other compounds targeting expressed PACAP and/or VIP include soluble fragments of PACAP receptors.
- the invention also relates to molecules that neutralize the activity of PACAP and/or VIP by interfering with its dimerisation, receptor-binding and/or receptor-binding-mediated signal transduction.
- molecules it is meant peptides, tetrameric peptides, proteins, organic molecules, mutants of PACAP or VIP, soluble receptors of the PACAP receptor (PACAPR), VPAC1 or VPAC2 and any fragment or homologue thereof having the same neutralizing effect as stated above.
- the present invention relates to the inhibition of PACAP signalling by targeting one or more of a receptor for PACAP (capable of binding PACAP) and to compounds useful therefore.
- PACAP receptor (PACAPR) antagonists such as max.d.4 5 (Sakashita et al. Br. (2001) J. Pharmacol, 132: 1769-1776) and PACAP6-38 (Tohei et al. (2001) Neuro - endocrinol. 73, 68-74).
- Compounds with type II PACAP receptor (VPAC1 and VPAC2) antagonist properties comprise several N-terminal truncated or substituted VIP peptides such as [4CI-D-Phe6, Leu17]VIP, VIP(10-28) (Pandol et al. (1986) Am. J. Physiol.
- VPAC1 receptor selective antagonists known are for instance [AcHis(1), D-Phe(2), Lys(15), Leu(17)]VIP(3-7)/GRF(8-27) (Lema-Kisoka R et al. (2001) cited supra).
- PACAP receptor agonists are neutralising antibodies against VPAC1 or aptamers (3-dimensional nucleic acids that bind to molecular targets in a manner similar to antibodies) that bind to VPAC1 receptor (or against PACAP) thereby neutralising its activity.
- Antagonising peptides MAX65 and MAX65 NH 2 are described in U.S. Pat. No. 6,017,533.
- VIP antagonising peptides with modified amino and carboxyterminal groups are described in WO95/21294.
- Other VIP antagonising compounds are described in U.S. Pat. No. 5,217,953, U.S. Pat. No. 5,565,242 and U.S. Pat. No. 6,630,124.
- Small molecules that act as a PACAP receptor antagonist e.g. small organic molecules and other drug candidates can be obtained, for example, from combinatorial and natural product libraries.
- Random peptide libraries such as the use of tetrameric peptide libraries such as described in WO0185796, consisting of all possible combinations of amino acids attached to a solid phase support may be used in identifying compounds useful in the present invention.
- transdominant-negative mutant forms of PACAP-receptors e.g. a transdominant-negative receptor of VPAC1 or VPAC2 can be used to inhibit the signal transduction of PACAP or VIP.
- one aspect of inhibition of PACAP signalling refers to inhibition at the protein level (PACAP or VIP or any of a receptor for PACAP).
- the inhibition of PACAP signalling leads to a diminished interaction with its receptor and an inhibition of signal transduction.
- Preferably said inhibition is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even higher.
- the inhibition of compounds on PACAP signalling can be measured for example by platelet aggregation or measuring the release of compounds from platelets such as ATP or serotonin.
- the biological activity of other potential PACAP agonists or antagonist can be determined by (1) determining whether the compound binds to receptors for PACAP (Gottschall, et al.
- the present invention relates to the inhibition of PACAP signalling by preventing expression (transcription and/or translation) of the PACAP and/or VIP gene and/or by preventing expression of a receptor for PACAP in blood platelet precursors and to compounds useful therefore.
- This inhibition is particularly effective when done in hematopoietic stem cells or in megakaryocytes or precursor cells thereof.
- molecules that are useful for this aspect of the invention are anti-sense RNA and DNA molecules (e.g. polynucleotide sequences) or ribozymes that function to inhibit the translation.
- anti-sense RNA and DNA molecules e.g. polynucleotide sequences
- ribozymes that function to inhibit the translation.
- Small molecules can also interfere by binding on the promoter region of a gene and inhibiting the binding of a transcription factor on said promoter region so that no mRNA is produced.
- oligoribonucleotide sequences that include anti-sense RNA and DNA molecules and ribozymes that function to inhibit the translation of VPAC1 or VPAC2 mRNA or PACAP mRNA or VIP mRNA.
- Anti-sense RNA and DNA molecules act to directly block the translation of mRNA by binding to targeted mRNA and preventing protein translation.
- antisense DNA oligodeoxyribonucleotides derived from the translation initiation site can be used.
- Ribozymes are enzymatic RNA molecules capable of catalysing the specific cleavage of RNA.
- ribozyme action involves sequence specific hybridisation of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage.
- engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyse endonucleolytic cleavage of VPAC(1) RNA, PACAP RNA or VIP RNA sequences.
- Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, which include the following sequences, GUA, GUU and GUC.
- RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable.
- Both anti-sense RNA and DNA molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule.
- DNA sequences may be incorporated into a wide variety of vectors, which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters.
- RNA polymerase promoters such as the T7 or SP6 polymerase promoters.
- antisense cDNA constructs that synthesize anti-sense RNA constitutively or inducible, depending on the promoter used, can be introduced stably into cell lines.
- Inhibition of PACAP signalling through gene transcription and/or translation by these compounds according to the present invention is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even higher and can be measured by lowered mRNA or protein levels.
- the invention in one aspect relates to a method for increasing or maintaining platelet counts in a subject having thrombocytopenia or a subject at risk of developing thrombocytopenia, by administering to the subject an inhibitor of PACAP signalling.
- the invention relates to the use of an inhibitor of PACAP signalling for the manufacture of a medicament for the prevention or treatment of thrombocytopenia.
- the prevention or treatment against thrombocytopenia can be aimed at an increased level of active platelets. This means that platelet number becomes higher after administration of the inhibitor than prior to the administration.
- An amount effective to increase platelet counts in the subject is an amount, which causes an increase in the amount of circulating platelet levels.
- the actual levels of platelets achieved will vary depending on many variables such as the initial status of the immune system in the subject, i.e., whether the subject has mild to severe thrombocytopenia (e.g., resulting from an autoimmune disease or splenic sequestration). In general, the platelet levels of a subject who has severe thrombocytopenia will initially be very low.
- the administration of the inhibitor aims to increase the number of platelets by at least 20, 50, 75 or 100%. Depending on the initial status of the individual (severe or low thrombocytopenia or normal platelet number), the individual will, after the administration of the inhibitor, display a low thrombocytopenia, a normal platelet number or a platelet number of normal levels).
- administration of an inhibitor of the PACAP signalling pathway can be aimed at a maintenance of the number of active platelets (i.e. preventing a significant decrease in the number of platelets expected as a result of chemotherapy).
- compositions for inducing platelet production comprising an effective quantity of a PACAP inhibitor and/or VIP inhibitor and/or a PACAP receptor inhibitor can be in admixture with pharmaceutically acceptable diluents, carriers or excipients.
- This property of stimulating platelet production of the molecule should render it a useful adjunct in the therapy of patients suffering from acute thrombocytopenia, for example, as a result of chemo- or radiotherapy of various cancers.
- the present invention relates to a pharmaceutical composition comprising an inhibitor of PACAP signalling and an additional compound for enhancing megakaryocyte maturation such as thrombopoetin or Interleukin 11.
- the term medicament relates to a composition comprising molecules as described above and a pharmaceutically acceptable carrier or excipient (both terms can be used interchangeably) to treat diseases as indicated above.
- Suitable carriers or excipients known to the skilled man are saline, Ringer's solution, dextrose solution, Hank's solution, fixed oils, ethyl oleate, 5% dextrose in saline, substances that enhance isotonicity and chemical stability, buffers and preservatives.
- Other suitable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids and amino acid copolymers.
- the ‘medicament’ may be administered by any suitable method within the knowledge of the skilled person.
- the preferred route of administration is parenterally.
- the medicament of this invention will be formulated in a unit dosage injectable form such as a solution, suspension or emulsion, in association with the pharmaceutically acceptable excipients as defined above.
- the dosage and mode of administration will depend on the individual.
- the medicament is administered so that the compound, protein, polypeptide, peptide of the present invention is given at a dose between 1 ⁇ g/kg and 10 mg/kg, more preferably between 10 ⁇ g/kg and 5 mg/kg, most preferably between 0.1 and 2 mg/kg.
- it is given as a bolus dose.
- Continuous infusion may also be used and includes continuous subcutaneous delivery via an osmotic minipump. If so, the medicament may be infused at a dose between 5 and 20 ⁇ g/kg/minute, more preferably between 7 and 15 ⁇ g/kg/minute.
- Another aspect of administration for treatment is the use of gene therapy to deliver the above mentioned anti-sense gene or functional parts of the VPAC(1) gene, PACAP gene or VIP gene or a ribozyme directed against the VPAC(1) mRNA, PACAP mRNA, VIP mRNA or a functional part thereof or a genetic construct encoding a transdominant-negative mutant form of VPAC(1)-receptors.
- Gene therapy means the treatment by the delivery of therapeutic nucleic acids to patient's cells (extensively reviewed in Lever and Goodfellow (1995) Br. Med. Bull. 51, 1-242; Culver et al. (1995) Br. Med. Bull. 51, 192-204; Ledley, F. D. (1995) Hum. Gene Ther. 6, 1129).
- Gene therapy requires a method for delivering genes to the patient's cells and additional methods to ensure the effective production of any therapeutic genes. There are two general approaches to achieve gene delivery; these are non-viral delivery and virus-mediated gene delivery.
- Another aspect of the invention relates the use of an inhibitor of PACAP signalling, i.e. a compound that inhibits the expression and/or activity of PACAP or VIP gene or a PACAP or VIP protein, for the manufacture of a medicament for treatment of platelet hypofunction.
- an inhibitor of PACAP signalling i.e. a compound that inhibits the expression and/or activity of PACAP or VIP gene or a PACAP or VIP protein
- An embodiment of the present invention relates to the use of molecules which comprise a region that can specifically bind to PACAP or to one of its receptors such as (VPAC(1) receptor) and which consequently interfere with the binding of PACAP and/or VIP to the VPAC(1) receptor, interfering with the signal transduction of PACAP and/or VIP.
- Said molecules can be used for the manufacture of a medicament for treatment of platelet hypofunction.
- Yet another aspect of the present invention relates to the use of stimulators of PACAP signalling in the prevention and treatment of thrombolytic disorders.
- stimulators of PACAP signalling include the 38-amino acid form of PACAP (PACAP38), HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2 and PACAP27, a 27-residue alpha-amidated polypeptide, HSDGIFTDSYSRYRKQMAVKKYLAAVL-NH2, which are both potent agonists of PACAPNIP receptors.
- PACAP 2-38, PACAP 2-27, AcHIS1 PACAP1-27, Ala2 PACAP(1-27) have also been demonstrated to be potent agonists of PACAP/VIP receptors (Vaudry D. et al. cited supra).
- PACAP receptor (PACAPR) selective agonists are, for instance, the compounds of the group consisting of the PACAP, VIP, [K(15), R(16), L(27)]VIP(1-7)/GRF(8-27), [R(16)]ChSn), (Lundberg et al. (2001) Endocrinology 142, 339-347; Lema-Kisoka R et al. (2001) Peptides 22, 2155-2162), [(11,22,28)Ala]-VIP (Anderson C. M. et al. (2003) Br. J. Pharmacol. 138, 564-73).
- VPAC1 Agonists of the type II PACAP receptor, VPAC1 are for instance compounds of the group consisting of [R(16)]-PACAP(1-23) and [(L22)]-VIP (Van Rampelbergh et al. (2000) Br. J. Pharmacol. 130: 819-26) and (Lys15, Arg16, Leu27)VIP1-7 GRF8-27 (Moody T W et al. (2000) Ann - N.Y. Acad. Sci. 921, 26-32).
- compositions comprising an activator of PACAP and/or a PACAP receptor agonist, preferably a VPAC(1) receptor agonist for treatment (particularly the prevention or suppression) of platelet hyperfunction in a subject.
- a pharmaceutical composition which comprises an amount of PACAP or a mimetic thereof effective for blocking or preventing thrombosis in a subject, and a pharmaceutically effective carrier.
- This pharmaceutical composition can be used to treat a subject having a thrombus or at risk of thrombus formation or to manufacture a medicament to treat a subject having a thrombus or at risk of thrombus formation.
- the present invention demonstrates that a pharmaceutical composition, which comprises an effective amount of above mentioned PACAP/VIP receptor agonist and a pharmaceutically effective carrier can be used to decrease platelet hyperfunction and/or for blocking or preventing thrombosis formation in a subject.
- Such pharmaceutical composition can be used to manufacture a medicament to treat a subject having a thrombus or at risk of thrombus formation.
- the invention thus provides compositions and methods useful for inhibiting, suppressing or ameliorating platelet hyperfunction in mammals, including humans.
- the invention has both human and veterinary applications.
- the inventive composition and method have been shown to be especially effective in preventing thrombosis formation.
- a new class of pharmaceutical compositions and methods of treatment and prevention of thrombosis and thrombosis related injury and disease is provided.
- the present invention also provides a pharmaceutical composition, which comprises an activator of PACAP or a PACAP receptor agonist, which in combination with an other antithrombotic agent, in an amount and proportion for enhancing the action of the other antithrombotic agent (e.g. aspirin, or an agent which blocks glycoprotein IIbIIIa, heparin, warfarin, coumarin derivatives, thrombin inhibitors, or Factor Xa inhibitors) to prevent clotting or dissolve clots which have already formed.
- an activator of PACAP or a PACAP receptor agonist which in combination with an other antithrombotic agent, in an amount and proportion for enhancing the action of the other antithrombotic agent (e.g. aspirin, or an agent which blocks glycoprotein IIbIIIa, heparin, warfarin, coumarin derivatives, thrombin inhibitors, or Factor Xa inhibitors) to prevent clotting or dissolve clots which have already formed.
- the present invention also provides a pharmaceutical composition, which comprises an activator of PACAP or a PACAP receptor agonist, in combination with an other antithrombotic agent, in an amount and proportion for enhancing the action of thrombolytic (e.g. staphylokinase, streptokinase, urokinase, tissue plasminogen activator, plasmin, mini- or microplasmin) to dissolve clots which have already formed
- thrombolytic e.g. staphylokinase, streptokinase, urokinase, tissue plasminogen activator, plasmin, mini- or microplasmin
- the present invention finds utility in other contexts where prevention of platelet hyperactivity is a significant concern, e.g. acute coronary syndrome, myocardial infarction, acute myocardial infarction, unstable angina, refractory angina, peripheral vascular disease, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular, syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombosis following angioplasty, restenosis following angioplasty, thrombosis following carotid endarterectomy, thrombotic thrombocytopenic purpura, thromboangitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications
- mice The bleeding time was determined as described before (Foster et al. (2001) J Clin Invest. 107:1591-1598.). Eight- to 15-week-old mice were bled under sodium pentobarbital anesthesia from the retro-orbital plexus. Mouse blood was collected in a saline solution containing 20 ⁇ g/mL hirudin. Preparation of PRP and aggregation were done as described above.
- Platelet cAMP was measured after incubating citrated PRP with Iloprost (1 ng/ml), arresting the reaction at different time points by addition of 12% trichloroacetic acid and using a cAMP enzyme-immunoassay (Amersham, Pharmacia Biotech). Basal cAMP levels in the platelets were measured in the presence of the phosphodiesterase inhibitor 3-isobutyl 1-methylxanthine (IBMX, 100 mM f.c.).
- IBMX phosphodiesterase inhibitor 3-isobutyl 1-methylxanthine
- Skin fibroblasts were obtained via punch biopsy from the volar side of the upper arm. Fibroblasts were cultured in DMEM/H12 (Invitrogen) supplemented with 10% fetal bovine serum and antibiotics (Invitrogen), at 37° C. in a 5% CO2 humidified incubator. Only fibroblasts of low passage number (between 6 and 12) were used for DNA and RNA extraction and for Camp measurements. Cells were grown to 100% confluence and then incubated in serum-free medium for 24 hours before cAMP analysis. Fibroblasts were plated in duplicate, one plate used for the assay, the other for cell counting; the obtained cAMP levels were thus adjusted for the cell number.
- FISH-analysis was performed on metaphase spreads following standard procedures (Pinkel et al. (1986). Proc. Natl. Acad. Sci. USA. 83: 2934-2938.), using a biotin labelled YAC 841C3 (Chang et al. (1993). Genomics. 17:393-402.) probe including the PACAP gene (ADCYAP1) locus at 18p11.31-32 in combination with two centromeric probes for chromosome 18 and 20.
- PACAP gene ADCYAP1
- RNA Approximately 1 mg of DNasel-treated fibroblast RNA, in the presence of an Rnasel inhibitor, was used for oligo (dT)-primed first strand cDNA synthesis using M-MLV reverse transcriptase (RT). The reverse transcriptase reaction was terminated by heating for 5 min at 95° C. The cDNA content was normalized using primers for b-actin.
- primer sets were used to generate specific fragments: b-actin beta5F 5′-ACCAACTGGGACGACATGGAG-3′ [SEQ ID NO: 6] and beta3R 5′-CGTGAGGATCTTCATGAGGTAGTC-3′ [SEQ ID NO: 7] and PACAP(1-38) PACAP4F 5′-GAAGCACCTGCAGTCGCTCG-3′ [SEQ ID NO: 8] and PACAP 2R 5′-TGTATACACAGGGTAGC-3′ [SEQ ID NO: 9]. All PCR reactions (with 17 and 20 cycles) were also performed in duplicate on separate fibroblast RNA samples.
- Plasma samples were deposited in the wells in PBS supplemented with 1% nonfat dry milk and 0.002% (v/v) Tween 80, overnight at 4° C.
- Bound PACAP(1-38) was revealed with secondary horseradish peroxidase-conjugated polyclonal anti-PACAP antibody (dilution 1/2500) and O-phenylenediamine. A dilution series of recombinant PACAP(1-38) served as a quantitative standard. All animal experiments were approved by the institutional review board and were conducted according to the guidelines for animal experiments of the National Institutes of Health.
- the murine GPIIb promoter (extending from +23 to 508 relative to the initiation start site) was excised from the mGPIIb-pGL3 plasmid by digestion with KpnI and BamHI and inserted into the KpnI-BamHI-digested PACAP-pcDNA3.1 vector (Invitrogen) in front of the mouse PACAP gene (Denarier et al. (1993), Biochem. Biophys. Res. Commun. 195:1360-1364).
- the mouse PACAP gene was amplified from brain cDNA with primers mPACAP1R 5′-GTAGCCGCTCGAGGATCTGCTACAAGTATGC-3′ [SEQ ID NO: 3] and mPACAP4F 5′-GTTAGCCGAATTCAGTTCAAGGTCTGGCTAG-3′ [SEQ ID NO: 4], sequenced, and cloned into the EcoRI-XhoI site of the pcDNA3.1 vector.
- the 2.2-kilobase (kb) KpnIDraIII fragment (GPIIb-PACAP) was excised and purified for zygote injection.
- mice The GPIIb promoter has been successfully used to restrict transgene expression to the megakaryocytic cell lineage of mice (Tronick-Le Roux et al. (1995) J. Exp. Med. 181:2141-2151).
- Transgenic PACAP overexpressing mice were generated by zygote injection into the Friend leukemia virus, strain B (FVB) background according to previously published procedures (Oury et al. (2003) Blood. 101:3969-3976; Holvoet et al. (1997) Eur. J. Biochem. 245:642-647).
- Transgenic offspring were identified by PCR screening using genomic DNA extracted from tail samples. The following primer pair was used: mGPIIb1F 5′-TGGCCACATCACAGCATTCAAG-3′ [SEQ ID No: 5] and mPACAP1R
- FIG. 1 represents a family characterised by an unbalanced segregation of the reciprocal translocation t(18;20) (p21;p13), of which different members suffer from unexplained mental retardation.
- the propositus (VI:1) is a 23-year-old boy with a hypogonadotropic hypogonadism and is followed for epilepsy, severe mental retardation, hyperactive behaviour and hypotonia. He has an increased bleeding tendency and the Ivy bleeding time was markedly prolonged (>15 minutes) but coagulation studies are normal. Electron microscopy of his platelets is completely normal but he presented on different occasions with a moderate thrombocytopenia, as his platelet count is always about 70-90 ⁇ 10 3 platelets/ ⁇ l.
- His karyotype shows a partial trisomy 18p and monosomy 20p.
- His brother (VI:2), father (V:2) and maternal grandmother (IV:6) are phenotypically normal, have no bleeding problems and have a normal karyotype.
- his mother (V:3) and maternal grandfather (IV:5) have no obvious neurologic abnormalities but a borderline IQ. They carry the balanced translocation t(18,20) (p21,p13). They don't have any obvious bleeding problems and have a normal platelet count.
- His 47-year-old uncle (V:4) also suffers from severe mental retardation, pronounced recurrent epistaxis and cryptorchidism.
- the propositus VI:1 has disturbed platelet function with a gain-of-Gs activity measured by the platelet aggregation inhibition test, similar to patients with the XL ⁇ s insertion (Vaudry et al. (2000) cited supra; Freson et al. (2001) Thrombosis and Haemostasis 86:733-738).
- Platelets from the patients (VI:1 and V:4) with the partial trisomy 18p/monosomy 20p had a significantly increased sensitivity towards a Gs agonist, the prostacyclin analogue Iloprost (table 1), while platelets from the family members (IV:5 and V:3) with the balanced translocation showed a moderately increased sensitivity.
- the IC 50 value for member IV:6 with the normal karyotype is within the rage of the IC 50 values from 22 unrelated controls.
- a significantly (P ⁇ 0.03* or P ⁇ 0.0076**) lower IC 50 value indicates a Gs hyperfunction.
- the right column of this table illustrates the significantly decreased response to collagen ( ⁇ g/ml) for respectively IV:5 and V:3 (P ⁇ 0.003*) versus V:4 and VI:1 (P ⁇ 0.0001**) compared to 10 controls or IV:6.
- EC 50 is expressed as collagen concentration that induces aggregation with amplitude 50% of maximal aggregation.
- Patient VI:1 has a normal Gs ⁇ mRNA and protein expression level and the coding sequence for the Gs ⁇ gene and XL-exon1 were completely normal.
- PACAP(1-38) Human skin fibroblasts express PACAP(1-38) and the PACAP type1-receptor (VPAC1) (Steinhoff M, et al. Regul Pept (1999), 80: 49-55).
- PACAP(1-38) mRNA was overexpressed in fibroblasts from patient VI:1 ( FIG. 3A ) by semi-quantitative RT-PCR. No PACAP mRNA was found in platelets by RT-PCR, probably due to their unstable RNA. However, western blot analysis showed that platelets express the VPAC1 receptor.
- PACAP The active peptide PACAP (1-38) is mainly expressed in testis and brain but this peptide can cross the blood-brain barrier and is stably transported in plasma through coupling with ceruloplasmin (Banks W A, J Pharmacol Exp Ther (1993) 267: 690-696; Tams JW, Biochem J (1999) 341: 271-2768, 9). PACAP is expressed in the human megakaryocytic cell lines MEG-01, DAM1 and K562 and a rather weak expression was found in control platelets by RT-PCR ( FIG. 3B ). Western blot analysis further revealed that platelets express the VPAC1 receptor, the levels of which were normal in the patient ( FIG. 3C ).
- PACAP(1-38) was detected in human plasma by ELISA and significantly higher levels were found in patients VI:1 and V:4, and moderately increased levels in IV:5 and V:3, in contrast to a plasma pool of unrelated controls or IV:6 ( FIG. 3D ).
- PACAP(6-38) enhanced the collagen-induced aggregation of normal human platelets in a dose-dependent manner ( FIG. 4B ) and decreased basal cAMP levels (data not shown).
- the PACAP antagonist also induced a partial but consistent improvement of the collagen-induced platelet aggregation in the patient ( FIG. 4B ).
- FVB mice were injected three times subcutaneously with 200 mg of an anti-PACAP or a control anti-b2-glycoprotein I polyclonal antibody or four times with 50 mg of an anti-PACAP (PP1A4) or an anti-RGS2 monoclonal antibody with an interval of 3 days between injections.
- whole blood from the inferior vena cava of mice anesthetized by intraperitoneal injection of 60 mg/kg sodium pentobarbital was drawn into 20 ⁇ g/mL hirudin.
- a platelet count was performed on the venous blood sample using the Cell Dyne 1300 (Abbott).
- mice had a similar effect on platelet aggregation as the PACAP antagonist PACAP(6-38).
- Platelets incubated with anti-PACAP antibodies (10 ⁇ g/ml) show an enhanced response towards collagen stimulation ( FIG. 5 ).
- mice treated with anti-PACAP antibodies show the opposite phenotype to that observed in patient VI:1.
- anti-PACAP-treated mice show a weaker response towards activation of the Gs pathway and have an enhanced response towards collagen stimulation ( FIG. 5A , B).
- Bone marrow from PACAP overexpressing and control mice was grown for 11 days in the presence of TPO, IL-6, IL-1b and SCF (Blair et al. (20022) Br. J. Haematol. 116:912-919.); FACS analysis showed a reduced expression of glycoprotein IIIa in megakaryocytes from the transgenic animals ( FIG. 5D ), indicative of a maturation defect.
- Transgenic mice present with a normal platelet count but their platelets have reduced levels of glycoprotein IIb/IIIa.
- the increased thrombocytopoiesis after pre-treatment with a polyclonal anti-PACAP antibody was studied under conditions of chemically suppressed bone marrow by the agent busulfan. This was done by subcutaneous injection of mice with either a polyclonal anti-PACAP or a control polyclonal antibody (at days 0, 3, and 7) and afterwards an intraperitonal injection of Busulfan (20 mg/kg) (at days 8 and 11). The platelet number was counted at different time points. Mice pretreated with the polyclonal anti-PACAP antibody recovered more rapidly from their thrombocytopenic condition than the mice injected with the control antibody ( FIG. 8A , B).
- PACAP monoclonal antibodies
- the same methodology can be used for shorter versions of PACAP (n terminally or c terminally truncated).
- the same methodology can also be used for a full length PACAP receptor or for a fragment thereof.
- Preferred fragments of a PACAP receptor are the extracellular domains of these receptors.
- a recombinant human PACAP(1-38) fusion protein consisting of the amino acids encoded by the PACAP(1-38) peptide coupled to Glutathione S-transferase (GST) was expressed in Escherichia coli and purified by affinity chromatography on immobilized glutathione (Amersham Biosciences).
- Recombinant human PACAP(1-38) is mixed with an equal amount of an adjuvant, and an obtained mixture is than subcutaneously administrated to Balb/c male mice (8 weeks old upon the start of immunization) in an amount corresponding to an amount of PACAP(1-38) of 100 ⁇ g per 1 mouse (priming immunization).
- immunization can be performed by subcutaneous administration in the same manner as described above (booster immunization).
- the mice can administrated through their tail veins with 200 ⁇ l of a preparation obtained by diluting human PACAP(1-38) with PBS (phosphate-buffered physiological saline) to have a concentration of 250 ⁇ g/ml (final immunization).
- Spleens have than to be excised from the mice after about 3 days from the final immunization, and they have to be separated into single cells. Subsequently, the spleen cells should be washed with a proper medium, e.g. DMEM medium.
- mouse myeloma cells e.g. Sp2/0-Ag14
- a proper medium e.g. DMEM medium.
- the spleen cells and the mouse myeloma cells have to be sufficiently mixed in a plastic tube in a ratio of numbers of the cells of 10:1, followed by addition of 50% (w/v) polyethylene glycol (PEG e.g. of Boehringer Mannheim, average molecular weight: 4000) to perform cell fusion at 37° C. for 7 minutes.
- PEG polyethylene glycol
- HAT medium DMEM medium containing 10% fetal bovine serum added with hypoxanthine, aminopterin, and thymidine.
- HAT medium DMEM medium containing 10% fetal bovine serum added with hypoxanthine, aminopterin, and thymidine.
- the residue has to be suspended so that a concentration of the spleen cells of about 5 ⁇ 106 cells/ml is obtained.
- This cell suspension can than be dispensed and poured into 96-well plastic plates so that one well contains about 100 ⁇ l of the suspension, followed by cultivation at 37° C. in 5% carbon dioxide.
- HAT medium has to be supplemented; for instance in an amount of 50 ⁇ l/well on 2nd and 5th days. After that, half volume of the medium can be exchanged every 3 or 4 days in conformity with proliferation of hybridomas.
- Hybridomas which produce the monoclonal antibody of the present invention, have to be screened for. This has to be done by using, as an index, the inhibitory activity of the monoclonal antibody on the physiological activity possessed by PACAP.
- Hybridomas which produced monoclonal antibodies exhibiting reactivity with PACAP's have then to be selected from the selected clones.
- the obtained hybridomas have then to be transferred to a suitable medium for instance HT medium which is the same as HAT medium except that aminopterin is removed from HAT medium, and cultured further. Cloning can be performed twice in accordance with the limiting dilution method by which stable hybridomas are obtainable.
- 2.6,10,14-Tetramethylpentadecane (e.g. Pristane of Sigma, 0.5 ml) can be intraperitoneally injected into Balb/c female mice (6 to 8 weeks old from the birth). After 10 to 20 days, cells of clones can be (1 ⁇ 10 6 to 10 7 cells) suspended in PBS and intraperitoneally inoculated into the mice. After 7 to 10 days, the mice can be sacrificed and subjected to an abdominal operation, from which produced ascitic fluid can be collected. The ascitic fluid can be centrifuged to remove insoluble matters, and a supernatant was recovered and stored at ⁇ 20° C.
- Pristane of Sigma 0.5 ml
- IgG can be purified from the ascitic fluid supernatant described above by using Hi-Trap Protein-A antibody purification kit (available from Pharmacia, Roosendaal, Netherlands). Namely, the ascitic fluid (2 ml) can be added with Solution A (1.5 M glycine, 3 M NaCl, pH 8.9, 8 ml), and filtrated with a filter for filtration having a pore size of 45 ⁇ m (Millipore). After that, an obtained filtrate can applied to a column (column volume: 1 ml) charged with Protein Sepharose HP (produced by Pharmacia) sufficiently equilibrated with Solution A, and the column has be washed with Solution A in an amount of 10-fold column volume.
- Solution A 1.5 M glycine, 3 M NaCl, pH 8.9, 8 ml
- a filter for filtration having a pore size of 45 ⁇ m (Millipore).
- an IgG fraction can be eluted with Solution B (0.1 M glycine, pH 2.8) in an amount of 10-fold column volume.
- the eluted IgG fraction can be dialyzed against PBS.
- the monoclonal antibodies can be determined for their IgG subclasses by using the purified antibodies obtained in the foregoing, by means of a commercially available subclass-determining kit (trade name: Mono Ab-ID EIA Kit A, produced by Zymed). This method is based on the ELISA method.
- the Inhibitory Activities of Monoclonal Antibodies can be tested for their possible stimulatory effect on collagen-induced (0.35 ⁇ g/ml) platelet aggregation of human or mouse platelets.
- VPAC1 have been cloned (Harmar et al. (1998) Pharmacol Rev. 50: 265-270).
- the human VPAC1 receptor DNA has been characterised from a HT29 human colonic adenocarcinoma cell line library. Human VPAC1 receptor comprises 457 amino acids (Sreedharan et al. (1993) Proc. Natl. Acad. Sci. USA 92: 2939-2943).
- the human VPAC1 receptor gene is located on region p22 of chromosome 3 (Sreedharan et al. (1995) Biochem Biophys Res Commun 193: 546-553). Cell lines, such Saccharomyces cerevisae , which are naturally devoid of VPAC1, can be transfected to produce such (Hansen MK (1999) Receptors Channels 6: 271-281). Vectors for expression of a PACAP receptor have been described in WO0107478. The method for preparation of a PACAP receptor protein has been disclosed in patent application US20020155533.
- F(ab′)2 or monovalent Fab fragments In order to prepare F(ab′)2 fragments, the monoclonal antibody can be dialyzed overnight against a 0.1 mol/L citrate buffer (pH 3.5). The antibody (200 parts) are then digested by incubation with pepsin (1 part) available from Sigma (Saint-Louis, Mo.) for 1 hour at 37° C. Digestion is consequently stopped by adding 1 volume of a 1 M Tris HCl buffer (pH 9) to 10 volumes of antibody.
- Monovalent Fab fragments can prepared by papain digestion as follows: a 1 volume of a 1M phosphate buffer (pH 7.3) is added to 10 volumes of the monoclonal antibody, then 1 volume papain (Sigma) is added to 25 volumes of the phosphate buffer containing monoclonal antibody, 10 mmol/l L-Cysteine HCl (Sigma) and 15 mmol/L ethylene diaminetetra-acetic acid (hereinafter referred to as EDTA). After incubation for 3 hours at 37′′ C, digestion is stopped by adding a final concentration of 30 mmol/l freshly prepared iodoacetamide solution (Sigma), keeping the mixture in the dark at room temperature for 30 minutes.
- EDTA ethylene diaminetetra-acetic acid
- Both F(ab′)2 and Fab fragments can further be purified from contaminating intact IgG and Fc fragments using protein-A-Sepharose.
- the purified fragments can finally dialyzed against phosphate-buffered saline (herein after referred as PBS).
- Purity of the fragments can be determined by sodiumdodecylsulphate polyacrylamide gel electrophoresis and the protein concentration can be measured using the bicinchonicic acid Protein Assay Reagent A (Pierce, Rockford, Ill.).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present application is a continuation of application Ser. No. 10/542,238, filed Jul. 15, 2005 (allowed), which is a U.S. national phase of PCT/EP2004/001209, filed Jan. 16, 2004, which claims benefit of GB application Nos. 0300934.7, 0307667.6, and 0310037.7, filed Jan. 16, 2003, Apr. 3, 2003 and Apr. 3, 2003, respectively.
- This invention relates to compounds useful in the control of the primary haemostasis and the modulation of platelet number, as well as methods of use of these compounds.
- The initial response to interruption of continuity of a blood vessel is defined as primary haemostasis. Platelets play a major role in the pathophysiology of primary haemostasis. The clinical importance of platelets first became obvious when thrombocytopenic patients, who later on were diagnosed as having immune mediated thrombocytopenia (ITP), had thrombocytopenic purpura. Platelets participate in haemostasis by sealing vascular injuries and by fostering the process of blood coagulation. Not only the number of the platelets is important (thrombocytopenia for whatever reason) but also their intrinsic function upon activation: change in platelet shape, adhesion, aggregation and secretion are prerequisites for normal haemostasis. Congenital or acquired disorders interfering with one of the platelet functions can lead to mild to even severe bleeding problems.
- Prevention and treatment of bleeding in patients with thrombocytopenia or thrombocytopathia is therefore based on platelet transfusion or medication interfering with platelet number and/or function.
- Platelets also play a role in the development of arterial thrombosis. Disruption of the endothelial cell lining of the vessels exposes adhesive proteins within the subendothelial matrix, leading to platelet attachment. Thereafter, platelet spreading, as well as platelet secretion occurs. The secretion of the content of platelet granules can stimulate circulating platelets to acquire new adhesive properties. Finally, stimulated platelets interact with each other during platelet aggregation and a platelet-rich thrombus is formed, which can compromise the patency of blood vessels. Furthermore activated platelets accelerate the rate of activation of coagulation proteins. Phospholipids on the platelet surface facilitate thrombin generation and fibrin strand formation.
- Arterial and venous thrombosis and their complications including ischemic stroke, acute myocardial infarction and venous thromboembolism, represent the major cause of morbidity and mortality in developed countries.
- Prevention and treatment of thrombosis are therefore based on administration of antiplatelet drugs, anticoagulants or thrombolytic therapy or combinations thereof.
- The pituitary Adenylyl Cyclase Activating Peptide (PACAP 1-38) is a 38-amino acid peptide that was first isolated from ovine hypothalamic extracts on the basis of its ability to stimulate cAMP formation in anterior pituitary cells [Miyata A. et al. (1989) Biochem Biophys Res Commun 164, 567-574; Vaudry D. et al. (2000) Pharm Rev 52, 269-324]. PACAP is a member of the Vasoactive Intestinal Polypeptide (VIP)-glucagon-growth hormone releasing factor-secretin superfamily. Its role in biology is probably crucial, since the sequence of PACAP is highly conserved during the evolution from protochordate to mammals. PACAP is widely expressed and occurs in the central and peripheral nervous system, the urogenital system, the gastro-intestinal tract, and in several endocrine glands. PACAP receptors are also widely distributed (Vaudray et al. cited supra). Two classes of PACAP binding sites have been characterized based on their relative affinities for PACAP and VIP: type I binding sites with high affinity for PACAP (Kd=0.5 nM) and much lower affinity for VIP (Kd>500 nM) and type II binding sites, which are widely distributed in various peripheral organs, characterised by similar affinities for PACAP and VIP (Kd=1 nM). Molecular cloning of PACAP receptors has demonstrated the existence of three distinct receptor subtypes that are abundantly spread in many tissues: the PACAP-specific PACAP receptor, coupled to different signal transduction systems, and two PACAP: VIP-indifferent receptors (VPAC1 and VPAC2, also referred to as VIPR1 and VIPR2, respectively), which are primarily coupled to adenylyl cyclase.
- The exact biological and pharmacological function of PACAP is presently being investigated in many organs and tissues as in endocrine glands, central nervous system, respiratory system, cardiovascular system and gastrointestinal tract. Although extensive studies have also been performed on its function in the immune system, limited data are available concerning its function on haemostasis. An effect of PACAP on aggregation and metabolism of isolated platelets has been described [Kis et al. (1999) Prostaglandins Other Lipid Mediat. 58:103-112 and Ichiki et al. (1992) Biochem Biophys Res Commun. 187, 1587-1593]. The occurrence of the VPAC1 receptor on platelets which binds both VIP as PACAP has been reported (Park et al. (1996) Blood 87, 4629-4635).
- The invention relates to the use of an inhibitor of PACAP signalling for the manufacture of a medicament for the prevention or treatment of thrombocytopenia. Herein the inhibitor of PACAP signalling can target expressed PACAP, expressed VIP or a receptor for PACAP. A receptor for PACAP can be the PACAP receptor (PACAPR), VPAC1 or VPAC2. The inhibitor can be an antagonist which interferes with PACAP, VIP or a PACAP receptor protein. Alternatively the inhibitor can inhibit the transcription or translation of PACAP, VIP or a receptor for PACAP. Examples of inhibitors of transcription and translation include an antisense molecule, an RNAi, an aptamer, a small molecule, an antibody, a ribozyme, a transdominant receptor, and a tetrameric peptide. Specific compounds having an inhibitory effect on PACAP signalling include max.d.4 5, PACAP6-38, [4CI-D-Phe6, Leu17]VIP, VIP(10-28), cyclic lactam analogs of PACAP, [AcHis(1), D-Phe(2), Lys(15), Leu(17)]VIP(3-7)/GRF(8-27), PACAP receptor blocking Cyclic lactam PACAP analogs, N-terminal truncated or substituted VIP peptide PACAP receptor blockers, neutralising antibodies against VPAC(1), and neutralising aptamer against VPAC(1) receptor, [4CI-D-Phe6, Leu17]VIP, VIP(10-28).
- The invention also relates to a pharmaceutical composition comprising an inhibitor of PACAP signalling and an additional compound for enhancing megakaryocyte maturation such as thrombopoetin or Interleukin 11.
- The invention also relates to the use of pituitary adenylyl cyclase activating peptide (PACAP), its derivatives, mimetics, antibodies or inhibitors for modulating the primary haemostasis or thrombocytopoiesis or the use of agonists or antagonists of the platelet receptor, VPAC1, to modulate the primary haemostasis or thrombocytopoiesis.
- The present invention further relates to a method for prevention as a prophylactic and for the treatment of either thrombosis or bleeding based on administration of pituitary adenylyl cyclase activating peptide (PACAP) mimetics or inhibitors respectively.
- The present invention shows that human platelets express the VPAC1 receptor. The present invention also shows that PACAP has an important function in primary haemostasis: platelet number as well as platelet function are highly influenced by PACAP.
- The invention provides compositions and methods useful for activating thrombocytopoiesis in mammals, including humans. The invention applies to human and veterinary applications. The inventive composition and method have been shown to be especially effective in treating platelet hypofunction.
- In addition, the present invention finds utility in e.g., radiation treatment or chemotherapeutic treatment or sickness caused by radiation accidents, where prevention or treatment of thrombocytopenia, anemia and neutropenia is a significant concern. The depletion of hematopoietic precursors in the bone marrow associated with chemotherapy and irradiation results in hemorrhagic and infectious complications. Severe suppression of the hematopoietic system is a major factor in limiting chemotherapy use and dose escalation.
- Compounds useful for exercising the thrombocytopoietic treatment or the manufacturing of a medicament for platelet hypofunction of present invention are thus compounds that inhibit the activity of PACAP or VIP and more specifically that antagonise the platelet receptor for PACAP.
-
FIG. 1 . Family presentation. Squares, male; circles, female; filled symbols, affected individuals; open symbols, unaffected individuals. Patient (VI:1) is the propositus. Black filled symbols represent members with severe mental retardation and a partial trisomy 18p and monosomy 20p, striped boxes represent members with borderline IQ and the balanced translocation t(18;20) (p21;p13) while question marks stand for members with unexplained mental retardation but unknown karyotype. -
FIG. 2 . Platelet aggregation and adenylyl cyclase activity. Measurements of cAMP levels under basal conditions (2A) performed in duplicate (left panel) or after stimulation with Iloprost (1 ng/ml) (2B) for various time intervals (right panel) in platelets from VI:1 (v) or an unrelated control (CrI)(X). Measurements of cAMP levels under basal conditions performed in duplicate (left panel) or after stimulation with isoproterenol (1 μM) for various time intervals (right panel) in fibroblasts from VI:1, a patient with trisomy 18 (σ) or an unrelated control (CrI) (X). All cAMP measurements were performed in the presence of the phosphodiesterase inhibitor IBMX (400 μM). -
FIG. 3 . PACAP detection in fibroblasts and plasma. 3A: Semi-quantitative RT-PCR using 20 cycles and 17 showed PACAP(1-38) overexpression in fibroblasts from patient VI:1 compared with two controls. β-actin is the internal control. 3B: PACAP mRNA detection in fibroblasts, megakaryocytic cell lines DAMI, MEG-01 and K562, and platelets was performed by RT-PCR. 3C: Immunoblot analysis of the VPAC1 receptor (58 kDa) in platelets from two unrelated controls and patient VI:1. 3D PACAP detections by ELISA in plasma from citrate (left panel) or ACD (acid citrate dextrose) (right panel) blood show pronounced or moderately increased PACAP level in respectively VI:1 (v) and V:4 (σ) or IV:5 (λ) and V:3 (ν) versus a citrated plasma pool (T) or IV:6 (Γ).3E. PACAP levels detected by ELISA in plasma (I) or serum (n) from mice (n=3). 3F. Collagen induced aggregation of control platelets in plasma from a control or from patient IV:1 (two experiments shown). -
FIG. 4 . Role of PACAP(6-38) in platelet aggregation. 4A: Left panel: the mean bleeding time (sec)+/−SD for 10 animals in each group (unpaired T-test; p=0.0001) from either wild type (WT) versus PACAP overexpressing (PACAP-Tg) mice. 4A Right panel: the collagen-induced (5 mg/ml) platelet aggregation in hirudinized PRP from 2 WT and two PACAP-Tg mice are shown. 4B: The left panel shows the dose-dependent stimulation by PACAP(6-38) of the collagen-induced (0.2 μg/ml) aggregation of human platelets; representative tracings of five separate experiments. The effect of PACAP (6-38) on the collagen-induced platelet aggregation (2 microgramg/ml) for patient VI:1 is illustrated in the right panel. 4C: The platelet aggregation inhibition test with collagen (2 μg/ml) and different concentrations of Iloprost (ng/ml) as indicated in the absence (left panels) and presence (right panels) of PACAP(6-38) for a control (upper panels) or patient VI:1 (lower panels). -
FIG. 5 . Effect of anti-PACAP antibodies in mice. Platelet aggregation was performed in PRP pooled from five mice of each group with 250×103 plt/μl. 5A: The platelet aggregation inhibition test with collagen (2 μg/ml) and preincubation of Iloprost (10 ng/ml) for mice injected with the indicated antibodies. 5B: Platelet aggregation induced with a low concentration of collagen (0.2 μg/ml) for mice injected with the indicated antibodies. 5C: Stimulatory effect of a polyclonal anti-PACAP antibody (10 μg/ml) on collagen-induced (0.35 μg/ml) platelet aggregation. - Effect of PACAP on thrombopoiesis. 5D: FACS analysis showed a reduced expression of glycoprotein IX (CD42a) in platelets from patient VI:1 versus control platelets (left panel) and a reduced expression of glycoprotein IIIA (CD61) in the megakaryocytes of the PACAP overexpressing mice compared to cells of the control mice (right panel). These experiments were repeated twice with identical results. 5E: Electron micrograph of megakaryocyte progenitor cell. Specific granules are seen as well as a dense core vesicle (arrow). A few endoplasmic reticulum cisternae are obvious. Original magnification: ×18.500. 5F: Mean platelet number+/−SD in mice (n=5) injected with either polyclonal anti-PACAP (group A) or monoclonal anti-human vWF (75H4B12) (group B) antibody, determined on the indicated days.
-
FIG. 6 . The mean platelet number per μl for mice (n=5) injected with either polyclonal anti-PACAP (6A) or an irrelevant anti-β2-glycoprotein I (6B) antibody was determined 14 days after the first antibody injection. -
FIG. 7 . Mean platelet number+/−SD for mice (n=5) injected with either polyclonal anti-PACAP (bars indicated with A) or anti-vWF (75H4B12) (bars indicated with B) antibody determined at the indicated days. -
FIG. 8 . Mean platelet number/μl+/−SD for mice (n=5) injected with either polyclonal anti-PACAP (bars indicated with A) or an irrelevant anti-XLαs (bars indicated with B) polyclonal antibody determined at the indicated days. Data represent separated experiments A (top figure) and B (bottom figure). - “PACAP” refers to Pituitary Adenylate Cyclase-Activating Polypeptide and refers to the mature and processed versions of the mature PACAP as PACAP(1-48) and more particularly to processed isoforms PACAP(1-38) HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2 [SEQ ID NO:1] and PACAP(1-27) HSDGIFTDSYSRYRKQMAVKKYLAAVL-NH2 [SEQ ID NO:2]. PACAP refers to PACAP of vertebrates, including mammalian PACAP and human PACAP.
- “VIP” refers to Vasoactive Intestinal Peptide (VIP), a 28-amino acid peptide which exhibits a wide variety of biologic actions. Because VIP shows similarities to glucagon, secretin and gastric inhibitory peptide (GIP), it has been considered a member of the glucagon-secretin family. The primary translation product of the mRNA encoding VIP (prepro-VIP) has a molecular weight of 20 daltons.
- “receptor for PACAP” refers to a receptor which is bound and activated by PACAP including the PACAP receptor (PACAPR) [OMIM 102981] which is specific for PACAP but also to VPAC1 (VIPR1) [OMIM 192321] and VPAC2 (VIPR2) [OMIM 601970] receptors which bind both PACAP and VIP (Vasoactive Intestinal peptide).
- As used herein, “thrombocytopenia” is any disorder in which the platelet level in the affected individual fall below a normal range of platelet numbers for that individual, due to disturbance in production distribution or destruction. In humans, normal blood platelet levels range from about 150.000 to 300.000 per microliter peripheral blood. With a platelet level of 100.000 per microliter patients have no abnormal bleeding even with major surgery; with a platelet count of 50.000 to 100.000 per microliter, patients may bleed longer than normal with severe trauma; with a platelet count of 20.000 to 50.000 per microliter, bleeding occurs with minor trauma but spontaneous bleeding is unusual; with a platelet count of less than 20.000, patients may have spontaneous bleeding and when the platelet count is less than 10.000 per microliter, patients are at high risk for severe bleeding.
- Thrombocytopenia also refers to a decrease in platelet number in an individual when compared to the platelet number measured at a certain reference point in that individual. The decrease in platelet number in the individual can be a decrease in more than 20%, 30%, 40%, 60%, 80%, 90%, 95% or even more, compared to value at the reference point. A decrease in platelet number when compared to the platelet number measured at a certain reference point, can in certain individuals be accompanied with changes in bleeding, while in other individuals a comparable decrease will not be accompanied with changes in bleeding. The reference point mentioned, can be for instance the start of a therapy such as a radiation or chemotherapy.
- Thrombocytopenia includes infection-induced thrombocytopenia, treatment-induced thrombocytopenia and others.
- “Infection-induced thrombocytopenia” is a disorder characterised by a lowered level of platelets in peripheral blood, which is caused by an infectious agent such as a bacteria or virus.
- “Treatment-induced thrombocytopenia” is a disorder characterised by a lowered level of platelets in peripheral blood which is caused by therapeutic treatments such as gamma irradiation, therapeutic exposure to radiation, cytotoxic drugs, chemicals containing benzene or anthracene and even some commonly used drugs such as chloramphenicol, thiouracil, and barbiturate hypnotics.
- “Other types of thrombocytopenia” comprise disorders characterised by a low level of platelets in peripheral blood, which are caused by any mechanism other than infectious agents or therapeutic treatments causing thrombocytopenia. Factors causing this type of thrombocytopenia include, but are not limited to, rare bone marrow disorders such as congenital amegakaryocytic hypoplasia and thrombocytopenia with absent radii (TAR syndrome), an increase in spleen size, or splenomegaly, caused by portal hypertension, secondary to liver disease, or macrophage storage disorders such as Gauchers disease, autoimmune disorders such as idiopathic or immune thrombocytopenic purpura (ITP), vasculitis, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura (TTP), disseminated intravascular coagulation (DIC) and prosthetic cardiac valves. ITP is by far the most frequent type in this group of thrombocytopenias.
- A “subject having thrombocytopenia” is a subject having any type of thrombocytopenia and includes but is not limited to non-chemotherapeutic-induced thrombocytopenia, or chemotherapeutic-induced thrombocytopenia.
- “A subject at risk of developing thrombocytopenia” is a subject who has a high probability of acquiring or developing thrombocytopenia. For example, a patient with a malignant tumour who is prescribed a chemotherapeutic treatment is at risk of developing treatment-induced thrombocytopenia and a subject who has an increased risk of exposure to infectious agents is at risk of developing infection-induced thrombocytopenia.
- “PACAP signalling” refers to the binding and activation of a receptor for PACAP. It thus relates to the binding of PACAP to the PACAC receptor, VPAC1 or VPAC2 r and subsequent activation. Moreover PACAP signalling also includes binding and activation of VPAC1 and VPAC2 by VIP. In a particular embodiment “PACAP signalling” relates to signalling via the VPAC1 receptor present on megakaryocytes in bone marrow.
- “Inhibition of PACAP signalling” refers to the inhibition of the binding of PACAP or VIP to a receptor for PACAP, which includes inhibition of the production and/or activity of the ligands PACAP and/or VIP (PACAP or VIP inhibition by PACAP and/or VIP inhibitors) and inhibition of the production or function of one or more receptors for PACAP or the binding of PACAP or VIP thereto (PACAP receptor inhibition), e.g. by antibodies, antagonists, soluble receptors, antisense etc, as detailed herein. These molecules are also generally referred to herein as ‘inhibitors of PACAP signalling’.
- The term ‘anti-PACAP antibody or antibodies’ relates to an antibody or antibodies characterised as being specifically directed against PACAP, VIP or any functional derivative thereof, with said antibodies being preferably monoclonal antibodies or an antigen-binding fragment thereof, of the F(ab′)2, F(ab) or single chain Fv type, or any type of recombinant antibody or antibody fragment derived thereof. Preferably, said antibody or fragment thereof is humanized or is in other ways appropriate for injection into the subject to be treated therewith.
- The term ‘anti-PACAP Receptor antibody or antibodies’ relates to an antibody or antibodies characterised as being specifically directed against one or more of thereceptors for PACAP (PACAPR, VPAC1 and VPAC2) with said antibodies being preferably monoclonal antibodies; or an antigen-binding fragment thereof, of the F(ab′)2, F(ab) or single chain Fv type, or any type of recombinant antibody derived thereof.
- These antibodies of the invention, including specific polyclonal antisera prepared against a receptor for PACAP, the ligands PACAP, VIP, or any functional derivative thereof, have no cross-reactivity to other proteins. The monoclonal antibodies of the invention can, for instance, be produced by any hybridoma produced according to classical methods using splenic cells of an animal, particularly of a mouse or rat immunized against a receptor for PACAP, PACAP, VIP, a molecule involved in PACAP signalling, or any functional derivative thereof, and cells of a myeloma cell line, and can be selected by the ability of the hybridoma to produce the monoclonal antibodies recognizing a receptor for PACAP, PACAP, VIP, the molecule involved in PACAP signalling, or any functional derivative thereof which has been initially used for the immunization of the animals.
- The monoclonal anti-PACAP or antibodies against a receptor for PACAP according to the invention may be humanized versions of the non-human monoclonal antibodies, made by means of recombinant DNA technology, departing from the mouse and/or human genomic DNA sequences coding for H and L chains or from cDNA clones coding for H and L chains. Alternatively the monoclonal antibodies according to this embodiment of the invention may be human monoclonal antibodies. Such human monoclonal antibodies are prepared, for instance, by means of human peripheral blood lymphocytes (PBL) repopulation of severe combined immune deficiency (SCID) mice as described in PCT/EP99/03605 or by using transgenic non-human animals capable of producing human antibodies as described in U.S. Pat. No. 5,545,806. Also fragments derived from these monoclonal antibodies such as Fab, F(ab)′2 and ssFv (“single chain variable fragment”), provided they have retained the original binding properties, form part of the present invention. Such fragments are commonly generated by, for instance, enzymatic digestion of the antibodies with papain, pepsin, or other proteases. It is well known to the person skilled in the art that monoclonal antibodies, or fragments thereof, can be modified for various uses. An appropriate label of the enzymatic, fluorescent, or radioactive type can label the antibodies involved in the invention.
- “stimulation of PACAP signalling” refers to the stimulation of a signal caused by the binding of PACAP, VIP or an agonist thereof to a receptor for PACAP which includes stimulation of the production or increase of the presence of the ligands PACAP and/or VIP, or agonists thereof or stimulation of the production or activity of one or more of a receptor for PACAP or the binding of PACAP or VIP thereto (PACAP receptor stimulation), e.g. by agonists, co-expression of PACAP or VIP-like molecules, etc, as detailed herein. These molecules are also generally referred to herein as ‘stimulators of PACAP signalling’.
- The term “pharmaceutically acceptable” is used to indicate that a compound used in the manufacture of the medicament is appropriate, for example with respect to specific activity or purity. The term “treatment” or “prevention” refers to any process, action, application, therapy, or the like, wherein a subject or individual is subjected to medical aid with the object of improving or maintaining the mammal's condition, directly or indirectly. Subject, individual or patient refers to a mammal and includes a laboratory animal, pet, agriculture animal; examples include dogs, cats, horses, rodents (rats, mice, hamsters, guinea pigs), cattle, pigs, rabbits, goats, among others. A mammal also refers to monkeys and primates, including humans.
- The present invention relates to the modulation of platelet function and number through the inhibition of PACAP signalling.
- In one aspect, the present invention relates to the inhibition of PACAP signalling by targeting PACAP and/or VIP in a subject and to compounds useful therefore.
- In a particular embodiment it relates to PACAP and/or VIP inhibition in the peripheral blood of a subject.
- Compounds which target expressed PACAP and/or VIP (referred to herein as examples of PACAP and/or VIP inhibitors) include polyclonal or monoclonal antibodies or antibody fragments against PACAP or VIP. Other compounds targeting expressed PACAP and/or VIP include soluble fragments of PACAP receptors. Thus more specifically the invention also relates to molecules that neutralize the activity of PACAP and/or VIP by interfering with its dimerisation, receptor-binding and/or receptor-binding-mediated signal transduction. By molecules it is meant peptides, tetrameric peptides, proteins, organic molecules, mutants of PACAP or VIP, soluble receptors of the PACAP receptor (PACAPR), VPAC1 or VPAC2 and any fragment or homologue thereof having the same neutralizing effect as stated above.
- In another aspect, the present invention relates to the inhibition of PACAP signalling by targeting one or more of a receptor for PACAP (capable of binding PACAP) and to compounds useful therefore.
- For instance, certain (poly)peptides are known to be PACAP receptor (PACAPR) antagonists such as max.d.4 5 (Sakashita et al. Br. (2001) J. Pharmacol, 132: 1769-1776) and PACAP6-38 (Tohei et al. (2001) Neuro-endocrinol. 73, 68-74). Compounds with type II PACAP receptor (VPAC1 and VPAC2) antagonist properties comprise several N-terminal truncated or substituted VIP peptides such as [4CI-D-Phe6, Leu17]VIP, VIP(10-28) (Pandol et al. (1986) Am. J. Physiol. 250: G553 G557; Turner et al. (1986), Peptides 7: 849-854; Gozes et al. (1995) Cell Mol Neurobiol. 15, 675-687; Gourlet et al. (1997) Peptides 18, 1555-60), cyclic lactam analogs of PACAP (Bitar at al. (1994) Peptides 15: 461-466). VPAC1 receptor selective antagonists known are for instance [AcHis(1), D-Phe(2), Lys(15), Leu(17)]VIP(3-7)/GRF(8-27) (Lema-Kisoka R et al. (2001) cited supra). Other PACAP receptor agonists are neutralising antibodies against VPAC1 or aptamers (3-dimensional nucleic acids that bind to molecular targets in a manner similar to antibodies) that bind to VPAC1 receptor (or against PACAP) thereby neutralising its activity. Antagonising peptides MAX65 and MAX65 NH2 are described in U.S. Pat. No. 6,017,533. VIP antagonising peptides with modified amino and carboxyterminal groups are described in WO95/21294. Other VIP antagonising compounds are described in U.S. Pat. No. 5,217,953, U.S. Pat. No. 5,565,242 and U.S. Pat. No. 6,630,124.
- Small molecules that act as a PACAP receptor antagonist, e.g. small organic molecules and other drug candidates can be obtained, for example, from combinatorial and natural product libraries. Random peptide libraries, such as the use of tetrameric peptide libraries such as described in WO0185796, consisting of all possible combinations of amino acids attached to a solid phase support may be used in identifying compounds useful in the present invention. Also transdominant-negative mutant forms of PACAP-receptors (e.g. a transdominant-negative receptor of VPAC1 or VPAC2 can be used to inhibit the signal transduction of PACAP or VIP.
- Thus, one aspect of inhibition of PACAP signalling refers to inhibition at the protein level (PACAP or VIP or any of a receptor for PACAP). The inhibition of PACAP signalling leads to a diminished interaction with its receptor and an inhibition of signal transduction. Preferably said inhibition is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even higher. The inhibition of compounds on PACAP signalling can be measured for example by platelet aggregation or measuring the release of compounds from platelets such as ATP or serotonin. The biological activity of other potential PACAP agonists or antagonist can be determined by (1) determining whether the compound binds to receptors for PACAP (Gottschall, et al. (1990) Endocrinology 127, 272; EP Application 529 487) and (2) determining whether the compound stimulates the production or release of PACAP. This can be assayed on isolated platelets or megakaryocytes or can be assayed in a cell culture system wherein cells are transfected with PACAPR, VPAC1 or VPAC2.
- In another aspect, the present invention relates to the inhibition of PACAP signalling by preventing expression (transcription and/or translation) of the PACAP and/or VIP gene and/or by preventing expression of a receptor for PACAP in blood platelet precursors and to compounds useful therefore. This inhibition is particularly effective when done in hematopoietic stem cells or in megakaryocytes or precursor cells thereof.
- Examples of molecules that are useful for this aspect of the invention are anti-sense RNA and DNA molecules (e.g. polynucleotide sequences) or ribozymes that function to inhibit the translation.
- Small molecules can also interfere by binding on the promoter region of a gene and inhibiting the binding of a transcription factor on said promoter region so that no mRNA is produced.
- Also within the scope of the invention is the use of oligoribonucleotide sequences that include anti-sense RNA and DNA molecules and ribozymes that function to inhibit the translation of VPAC1 or VPAC2 mRNA or PACAP mRNA or VIP mRNA. Anti-sense RNA and DNA molecules act to directly block the translation of mRNA by binding to targeted mRNA and preventing protein translation. With regard to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site can be used. Ribozymes are enzymatic RNA molecules capable of catalysing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridisation of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyse endonucleolytic cleavage of VPAC(1) RNA, PACAP RNA or VIP RNA sequences. Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. Both anti-sense RNA and DNA molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors, which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize anti-sense RNA constitutively or inducible, depending on the promoter used, can be introduced stably into cell lines.
- Inhibition of PACAP signalling through gene transcription and/or translation by these compounds according to the present invention is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even higher and can be measured by lowered mRNA or protein levels.
- The invention in one aspect relates to a method for increasing or maintaining platelet counts in a subject having thrombocytopenia or a subject at risk of developing thrombocytopenia, by administering to the subject an inhibitor of PACAP signalling.
- Thus the invention relates to the use of an inhibitor of PACAP signalling for the manufacture of a medicament for the prevention or treatment of thrombocytopenia.
- The prevention or treatment against thrombocytopenia can be aimed at an increased level of active platelets. This means that platelet number becomes higher after administration of the inhibitor than prior to the administration. An amount effective to increase platelet counts in the subject is an amount, which causes an increase in the amount of circulating platelet levels. The actual levels of platelets achieved will vary depending on many variables such as the initial status of the immune system in the subject, i.e., whether the subject has mild to severe thrombocytopenia (e.g., resulting from an autoimmune disease or splenic sequestration). In general, the platelet levels of a subject who has severe thrombocytopenia will initially be very low. Any increase in the platelet levels of such a subject, even an increase to a level that is still below a normal level, can be advantageous to the subject, since at the same time platelet function will be upregulated. The administration of the inhibitor aims to increase the number of platelets by at least 20, 50, 75 or 100%. Depending on the initial status of the individual (severe or low thrombocytopenia or normal platelet number), the individual will, after the administration of the inhibitor, display a low thrombocytopenia, a normal platelet number or a platelet number of normal levels). Alternatively, and more particularly in case of prevention of thrombocytopenia e.g. in combination with or before chemotherapy, administration of an inhibitor of the PACAP signalling pathway can be aimed at a maintenance of the number of active platelets (i.e. preventing a significant decrease in the number of platelets expected as a result of chemotherapy).
- The compositions for inducing platelet production, comprising an effective quantity of a PACAP inhibitor and/or VIP inhibitor and/or a PACAP receptor inhibitor can be in admixture with pharmaceutically acceptable diluents, carriers or excipients. This property of stimulating platelet production of the molecule should render it a useful adjunct in the therapy of patients suffering from acute thrombocytopenia, for example, as a result of chemo- or radiotherapy of various cancers. Currently, such patients are at grave risk when circulating platelet levels are depressed to levels whereby thrombogenesis is precluded. In a particular embodiment the present invention relates to a pharmaceutical composition comprising an inhibitor of PACAP signalling and an additional compound for enhancing megakaryocyte maturation such as thrombopoetin or
Interleukin 11. - The term medicament relates to a composition comprising molecules as described above and a pharmaceutically acceptable carrier or excipient (both terms can be used interchangeably) to treat diseases as indicated above. Suitable carriers or excipients known to the skilled man are saline, Ringer's solution, dextrose solution, Hank's solution, fixed oils, ethyl oleate, 5% dextrose in saline, substances that enhance isotonicity and chemical stability, buffers and preservatives. Other suitable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids and amino acid copolymers. The ‘medicament’ may be administered by any suitable method within the knowledge of the skilled person. The preferred route of administration is parenterally. For parenteral administration, the medicament of this invention will be formulated in a unit dosage injectable form such as a solution, suspension or emulsion, in association with the pharmaceutically acceptable excipients as defined above. However, the dosage and mode of administration will depend on the individual. Generally, the medicament is administered so that the compound, protein, polypeptide, peptide of the present invention is given at a dose between 1 μg/kg and 10 mg/kg, more preferably between 10 μg/kg and 5 mg/kg, most preferably between 0.1 and 2 mg/kg. Preferably, it is given as a bolus dose. Continuous infusion may also be used and includes continuous subcutaneous delivery via an osmotic minipump. If so, the medicament may be infused at a dose between 5 and 20 μg/kg/minute, more preferably between 7 and 15 μg/kg/minute.
- Another aspect of administration for treatment is the use of gene therapy to deliver the above mentioned anti-sense gene or functional parts of the VPAC(1) gene, PACAP gene or VIP gene or a ribozyme directed against the VPAC(1) mRNA, PACAP mRNA, VIP mRNA or a functional part thereof or a genetic construct encoding a transdominant-negative mutant form of VPAC(1)-receptors. Gene therapy means the treatment by the delivery of therapeutic nucleic acids to patient's cells (extensively reviewed in Lever and Goodfellow (1995) Br. Med. Bull. 51, 1-242; Culver et al. (1995) Br. Med. Bull. 51, 192-204; Ledley, F. D. (1995) Hum. Gene Ther. 6, 1129). Gene therapy requires a method for delivering genes to the patient's cells and additional methods to ensure the effective production of any therapeutic genes. There are two general approaches to achieve gene delivery; these are non-viral delivery and virus-mediated gene delivery.
- Another aspect of the invention relates the use of an inhibitor of PACAP signalling, i.e. a compound that inhibits the expression and/or activity of PACAP or VIP gene or a PACAP or VIP protein, for the manufacture of a medicament for treatment of platelet hypofunction. This is based on the finding that platelet hypofunction can be treated (activated) by inhibiting the expression and/or activity of PACAP.
- An embodiment of the present invention relates to the use of molecules which comprise a region that can specifically bind to PACAP or to one of its receptors such as (VPAC(1) receptor) and which consequently interfere with the binding of PACAP and/or VIP to the VPAC(1) receptor, interfering with the signal transduction of PACAP and/or VIP. Said molecules can be used for the manufacture of a medicament for treatment of platelet hypofunction.
- Yet another aspect of the present invention relates to the use of stimulators of PACAP signalling in the prevention and treatment of thrombolytic disorders. Examples of stimulators of PACAP signalling include the 38-amino acid form of PACAP (PACAP38), HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2 and PACAP27, a 27-residue alpha-amidated polypeptide, HSDGIFTDSYSRYRKQMAVKKYLAAVL-NH2, which are both potent agonists of PACAPNIP receptors. Based on their binding affinity and adenylyl cyclase stimulating properties, PACAP 2-38, PACAP 2-27, AcHIS1 PACAP1-27, Ala2 PACAP(1-27) have also been demonstrated to be potent agonists of PACAP/VIP receptors (Vaudry D. et al. cited supra).
- Amino acid substitutions and additions of a fatty acyl moiety have led to the development of lipophilic VIP derivatives that exhibit enhanced potency and specificity for VPAC receptors (Gozes and Fridkin, (1992) J. Clin. Invest 90: 810-814; Gozes et al. (1995) Cell Mol. Neurobiol. 15: 675-687; Gourlet et al. (1998) Eur. J. Pharmacol 354: 105-111).
- PACAP receptor (PACAPR) selective agonists are, for instance, the compounds of the group consisting of the PACAP, VIP, [K(15), R(16), L(27)]VIP(1-7)/GRF(8-27), [R(16)]ChSn), (Lundberg et al. (2001) Endocrinology 142, 339-347; Lema-Kisoka R et al. (2001) Peptides 22, 2155-2162), [(11,22,28)Ala]-VIP (Anderson C. M. et al. (2003) Br. J. Pharmacol. 138, 564-73).
- Agonists of the type II PACAP receptor, VPAC1 are for instance compounds of the group consisting of [R(16)]-PACAP(1-23) and [(L22)]-VIP (Van Rampelbergh et al. (2000) Br. J. Pharmacol. 130: 819-26) and (Lys15, Arg16, Leu27)VIP1-7 GRF8-27 (Moody T W et al. (2000) Ann-N.Y. Acad. Sci. 921, 26-32).
- An important embodiment of this aspect of the present invention relates to compositions comprising an activator of PACAP and/or a PACAP receptor agonist, preferably a VPAC(1) receptor agonist for treatment (particularly the prevention or suppression) of platelet hyperfunction in a subject. It can be a pharmaceutical composition, which comprises an amount of PACAP or a mimetic thereof effective for blocking or preventing thrombosis in a subject, and a pharmaceutically effective carrier. This pharmaceutical composition can be used to treat a subject having a thrombus or at risk of thrombus formation or to manufacture a medicament to treat a subject having a thrombus or at risk of thrombus formation.
- The present invention demonstrates that a pharmaceutical composition, which comprises an effective amount of above mentioned PACAP/VIP receptor agonist and a pharmaceutically effective carrier can be used to decrease platelet hyperfunction and/or for blocking or preventing thrombosis formation in a subject. Such pharmaceutical composition can be used to manufacture a medicament to treat a subject having a thrombus or at risk of thrombus formation.
- The invention thus provides compositions and methods useful for inhibiting, suppressing or ameliorating platelet hyperfunction in mammals, including humans. The invention has both human and veterinary applications. The inventive composition and method have been shown to be especially effective in preventing thrombosis formation. A new class of pharmaceutical compositions and methods of treatment and prevention of thrombosis and thrombosis related injury and disease is provided.
- The present invention also provides a pharmaceutical composition, which comprises an activator of PACAP or a PACAP receptor agonist, which in combination with an other antithrombotic agent, in an amount and proportion for enhancing the action of the other antithrombotic agent (e.g. aspirin, or an agent which blocks glycoprotein IIbIIIa, heparin, warfarin, coumarin derivatives, thrombin inhibitors, or Factor Xa inhibitors) to prevent clotting or dissolve clots which have already formed.
- The present invention also provides a pharmaceutical composition, which comprises an activator of PACAP or a PACAP receptor agonist, in combination with an other antithrombotic agent, in an amount and proportion for enhancing the action of thrombolytic (e.g. staphylokinase, streptokinase, urokinase, tissue plasminogen activator, plasmin, mini- or microplasmin) to dissolve clots which have already formed
- In addition, the present invention finds utility in other contexts where prevention of platelet hyperactivity is a significant concern, e.g. acute coronary syndrome, myocardial infarction, acute myocardial infarction, unstable angina, refractory angina, peripheral vascular disease, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular, syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombosis following angioplasty, restenosis following angioplasty, thrombosis following carotid endarterectomy, thrombotic thrombocytopenic purpura, thromboangitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation such as cardiac or other intravascular catherization, intra-aortic ballon pump, coronary stent, atherosclerosis, or cardiac valve, disorder is characterized by transient ischemic attacks, and conditions required the fitting of prosthetic devices.
- The following examples illustrate preferred features of the invention, but are not intended to limit the invention in any way. All of the starting materials and reagents disclosed below are known to those skilled in the art, and are available commercially or can be prepared using well-known techniques.
- Blood was anticoagulated with 3.8% (wt/vol) trisodium citrate (9:1) and platelet-rich plasma (PRP), obtained by centrifugation (15 minutes at 150 g), was recentrifuged (3000 g for 15 min) to obtain platelet-poor plasma (PPP-trisodium citrate). Finally the platelet count in the PRP was adjusted to 250×109 platelets/L with PPP. Platelet aggregation was performed on two dual-channel Chrono-Log Aggregometers (Chronolog Corp.), by simultaneously recording 4 tracings.
- Aggregation inhibition studies were done as described before (Freson et al. (2002) Thromb. Haemost. 86:733-738; Freson et al. (2003) Hum. Mol. Genet. 15:1121-1130) and involved dose-response curves to the stable prostacyclin analogue and Gs agonist Iloprost (Ilomedine; 0-5 ng/ml; Schering), which was added to
PRP 1 min prior to induction of aggregation by Horm collagen (Nycomed, Germany; 2 mg/ml). The 50% inhibitory concentration (IC50) was calculated after curve fitting using the software InStat 2.03. The IC50 values±SD were compared to the IC50 for the same Gs-agonist on control platelets, studied simultaneously. - The bleeding time was determined as described before (Foster et al. (2001) J Clin Invest. 107:1591-1598.). Eight- to 15-week-old mice were bled under sodium pentobarbital anesthesia from the retro-orbital plexus. Mouse blood was collected in a saline solution containing 20 μg/mL hirudin. Preparation of PRP and aggregation were done as described above.
- cAMP Detection in Platelets.
- Platelet cAMP was measured after incubating citrated PRP with Iloprost (1 ng/ml), arresting the reaction at different time points by addition of 12% trichloroacetic acid and using a cAMP enzyme-immunoassay (Amersham, Pharmacia Biotech). Basal cAMP levels in the platelets were measured in the presence of the phosphodiesterase inhibitor 3-isobutyl 1-methylxanthine (IBMX, 100 mM f.c.).
- Human Skin Fibroblasts and cAMP Detection.
- Skin fibroblasts were obtained via punch biopsy from the volar side of the upper arm. Fibroblasts were cultured in DMEM/H12 (Invitrogen) supplemented with 10% fetal bovine serum and antibiotics (Invitrogen), at 37° C. in a 5% CO2 humidified incubator. Only fibroblasts of low passage number (between 6 and 12) were used for DNA and RNA extraction and for Camp measurements. Cells were grown to 100% confluence and then incubated in serum-free medium for 24 hours before cAMP analysis. Fibroblasts were plated in duplicate, one plate used for the assay, the other for cell counting; the obtained cAMP levels were thus adjusted for the cell number. Patient or control fibroblasts were stimulated with the Gs agonist isoproterenol (Calbiochem) at 1 mM in the presence of a phosphodiesterase inhibitor (IBMX; 100 mM) and reactions were terminated by the cell lysis buffer supplied with the kit. The cAMP levels were measured using the cAMP enzyme-immunoassay mentioned above.
- FISH-analysis was performed on metaphase spreads following standard procedures (Pinkel et al. (1986). Proc. Natl. Acad. Sci. USA. 83: 2934-2938.), using a biotin labelled YAC 841C3 (Chang et al. (1993). Genomics. 17:393-402.) probe including the PACAP gene (ADCYAP1) locus at 18p11.31-32 in combination with two centromeric probes for
chromosome 18 and 20. - Semi-Quantitative Detection of PACAP(1-38) mRNA.
- Total RNA was extracted from cultured fibroblasts using TRIzol reagent according to the manufacturer's protocol.
- Approximately 1 mg of DNasel-treated fibroblast RNA, in the presence of an Rnasel inhibitor, was used for oligo (dT)-primed first strand cDNA synthesis using M-MLV reverse transcriptase (RT). The reverse transcriptase reaction was terminated by heating for 5 min at 95° C. The cDNA content was normalized using primers for b-actin. The following primer sets were used to generate specific fragments: b-
actin beta5F 5′-ACCAACTGGGACGACATGGAG-3′ [SEQ ID NO: 6] andbeta3R 5′-CGTGAGGATCTTCATGAGGTAGTC-3′ [SEQ ID NO: 7] and PACAP(1-38) PACAP4F 5′-GAAGCACCTGCAGTCGCTCG-3′ [SEQ ID NO: 8] andPACAP 2R 5′-TGTATACACAGGGTAGC-3′ [SEQ ID NO: 9]. All PCR reactions (with 17 and 20 cycles) were also performed in duplicate on separate fibroblast RNA samples. - Blood was anticoagulated with 3.8% (wt/vol) trisodium citrate (9:1) or acid citrate dextrose (ACD), pH 6.5 (9:1) and plasma (PPP) was obtained by centrifugation for 15 minutes at 3,000 g. A polyclonal anti-PACAP antibody was coated overnight at 4° C. in microtiter plates (Costar, high binding) at 10 mg/ml in 200 ml PBS. After blocking the plates with 1% nonfat dry milk in PBS, plasma samples (0-0.01 ml/200 ml) were deposited in the wells in PBS supplemented with 1% nonfat dry milk and 0.002% (v/v)
Tween 80, overnight at 4° C. Bound PACAP(1-38) was revealed with secondary horseradish peroxidase-conjugated polyclonal anti-PACAP antibody (dilution 1/2500) and O-phenylenediamine. A dilution series of recombinant PACAP(1-38) served as a quantitative standard. All animal experiments were approved by the institutional review board and were conducted according to the guidelines for animal experiments of the National Institutes of Health. - The murine GPIIb promoter (extending from +23 to 508 relative to the initiation start site) was excised from the mGPIIb-pGL3 plasmid by digestion with KpnI and BamHI and inserted into the KpnI-BamHI-digested PACAP-pcDNA3.1 vector (Invitrogen) in front of the mouse PACAP gene (Denarier et al. (1993), Biochem. Biophys. Res. Commun. 195:1360-1364). The mouse PACAP gene was amplified from brain cDNA with
primers mPACAP1R 5′-GTAGCCGCTCGAGGATCTGCTACAAGTATGC-3′ [SEQ ID NO: 3] andmPACAP4F 5′-GTTAGCCGAATTCAGTTCAAGGTCTGGCTAG-3′ [SEQ ID NO: 4], sequenced, and cloned into the EcoRI-XhoI site of the pcDNA3.1 vector. The 2.2-kilobase (kb) KpnIDraIII fragment (GPIIb-PACAP) was excised and purified for zygote injection. The GPIIb promoter has been successfully used to restrict transgene expression to the megakaryocytic cell lineage of mice (Tronick-Le Roux et al. (1995) J. Exp. Med. 181:2141-2151). Transgenic PACAP overexpressing mice were generated by zygote injection into the Friend leukemia virus, strain B (FVB) background according to previously published procedures (Oury et al. (2003) Blood. 101:3969-3976; Holvoet et al. (1997) Eur. J. Biochem. 245:642-647). Transgenic offspring were identified by PCR screening using genomic DNA extracted from tail samples. The following primer pair was used:mGPIIb1F 5′-TGGCCACATCACAGCATTCAAG-3′ [SEQ ID No: 5] and mPACAP1R -
FIG. 1 represents a family characterised by an unbalanced segregation of the reciprocal translocation t(18;20) (p21;p13), of which different members suffer from unexplained mental retardation. The propositus (VI:1) is a 23-year-old boy with a hypogonadotropic hypogonadism and is followed for epilepsy, severe mental retardation, hyperactive behaviour and hypotonia. He has an increased bleeding tendency and the Ivy bleeding time was markedly prolonged (>15 minutes) but coagulation studies are normal. Electron microscopy of his platelets is completely normal but he presented on different occasions with a moderate thrombocytopenia, as his platelet count is always about 70-90×103 platelets/μl. His karyotype shows a partial trisomy 18p and monosomy 20p. His brother (VI:2), father (V:2) and maternal grandmother (IV:6) are phenotypically normal, have no bleeding problems and have a normal karyotype. In contrast, his mother (V:3) and maternal grandfather (IV:5) have no obvious neurologic abnormalities but a borderline IQ. They carry the balanced translocation t(18,20) (p21,p13). They don't have any obvious bleeding problems and have a normal platelet count. His 47-year-old uncle (V:4) also suffers from severe mental retardation, pronounced recurrent epistaxis and cryptorchidism. Furthermore, he frequently has gastric bleedings and his platelet count is around 150×103 platelets/μl. He also has a partial trisomy 18p and monosomy 20p. Two other family members (IV:2 and V:1) are known with unexplained mental retardation but from these individuals no DNA samples or further clinical information are available. - The propositus VI:1 has disturbed platelet function with a gain-of-Gs activity measured by the platelet aggregation inhibition test, similar to patients with the XLαs insertion (Vaudry et al. (2000) cited supra; Freson et al. (2001) Thrombosis and Haemostasis 86:733-738). Platelets from the patients (VI:1 and V:4) with the partial trisomy 18p/monosomy 20p had a significantly increased sensitivity towards a Gs agonist, the prostacyclin analogue Iloprost (table 1), while platelets from the family members (IV:5 and V:3) with the balanced translocation showed a moderately increased sensitivity. The IC50 value for member IV:6 with the normal karyotype is within the rage of the IC50 values from 22 unrelated controls.
- An important difference between patients from this family and the patients with the XLαs insertion is their decreased sensitivity towards the platelet agonist such as collagen, ADP and U46619. The collagen concentration to obtain 50% aggregation for platelets from V:4 and VI:1 is significantly higher than for platelets from unrelated controls or the normal member IV:6 (Table 1). The reactivity of platelets from IV:5 and V:3 towards collagen is again mildly affected.
-
TABLE 1 IC50 value for Iloprost in the platelet aggregation inhibition test IC50 ± SD EC50 ± SD Iloprost Collagen IV:6 0.96 ± 0.002 0.25 ± 0.012 IV:5 0.50 ± 0.003* 0.74 ± 0.013 V3 0.47 ± 0.003* 0.75 ± 0.006 V4 0.27 ± 0.005** 1.08 ± 0.006 VI:1 0.34 ± 0.004** 1.03 ± 0.008 controls 1.04 ± 0.39 (n = 22) 0.22 ± 0.6 (n = 10) IC50 ± accuracy values for indicated individuals and the mean IC50 value for Iloprost in the platelet aggregation inhibition test with 2 μg/ml collagen in 22 controls were calculated. A significantly (P ≦ 0.03* or P ≦ 0.0076**) lower IC50 value indicates a Gs hyperfunction. The right column of this table illustrates the significantly decreased response to collagen (μg/ml) for respectively IV:5 and V:3 (P ≦ 0.003*) versus V:4 and VI:1 (P ≦ 0.0001**) compared to 10 controls or IV:6. EC50 is expressed as collagen concentration that induces aggregation with amplitude 50% of maximal aggregation. - For patients with the XLαs insertion, it has been shown that the functional responses mediated by stimulation of Gs agonists are due to hyperactivity of adenylyl cyclase only when Gs-coupled receptors are stimulated (Vaudry et al. (2000) cited supra; Freson et al. (2001) cited supra). These patients had normal basal cAMP levels. This indicates that in the platelets of the propositus VI:1, adenylyl cyclase is already activated under basal conditions. In addition to an increased cAMP response to Iloprost, patient VI:1 indeed shows higher basal cAMP levels (
FIG. 2A ). cAMP levels were measured in fibroblasts from VI:1. A similar increased basal and stimulated cAMP response (FIG. 2B ) was found. - C: PACAP(1-38) mRNA and Protein Overexpression
- Patient VI:1 has a normal Gsα mRNA and protein expression level and the coding sequence for the Gsα gene and XL-exon1 were completely normal.
- Since this patient had a partial trisomy 18p and monosomy 20p, these chromosomes were screened for candidate genes. Interestingly, measurement of the adenylyl cyclase activity in fibroblasts from an unrelated patient with a complete trisomy 18 showed similarly increased basal and stimulated cAMP levels (
FIG. 2B ). The gene for PACAP (ADCYAP1) is located on chromosome 18p31-32 (Hosoya M. et al. Biochim Biophys Acta (1992) 1129, 199-206.) and is a possible candidate since its active peptide, PACAP(1-38), stimulates Gs-coupled receptors and thereby activates adenylyl cyclase. FISH analysis with YAC clone Y841C3 (Chang E. et al. Genomics (1993) 17: 393-402.), that contains ACDYAP1, showed that the translocation results in three copies of the gene in patients VI.1 and V:4. - Human skin fibroblasts express PACAP(1-38) and the PACAP type1-receptor (VPAC1) (Steinhoff M, et al. Regul Pept (1999), 80: 49-55). PACAP(1-38) mRNA was overexpressed in fibroblasts from patient VI:1 (
FIG. 3A ) by semi-quantitative RT-PCR. No PACAP mRNA was found in platelets by RT-PCR, probably due to their unstable RNA. However, western blot analysis showed that platelets express the VPAC1 receptor. The active peptide PACAP (1-38) is mainly expressed in testis and brain but this peptide can cross the blood-brain barrier and is stably transported in plasma through coupling with ceruloplasmin (Banks W A, J Pharmacol Exp Ther (1993) 267: 690-696; Tams JW, Biochem J (1999) 341: 271-2768, 9). PACAP is expressed in the human megakaryocytic cell lines MEG-01, DAM1 and K562 and a rather weak expression was found in control platelets by RT-PCR (FIG. 3B ). Western blot analysis further revealed that platelets express the VPAC1 receptor, the levels of which were normal in the patient (FIG. 3C ). PACAP(1-38) was detected in human plasma by ELISA and significantly higher levels were found in patients VI:1 and V:4, and moderately increased levels in IV:5 and V:3, in contrast to a plasma pool of unrelated controls or IV:6 (FIG. 3D ). Platelet aggregation using washed control platelets resuspended in citrated plasma from a control or patient VI:1, indicated that plasma from VI:1 inhibits the collagen induced aggregation (FIG. 3D ). This could be due to the increased amount of PACAP(1-38) in this plasma. - To establish the role of circulating PACAP(1-38) as a physiological inhibitor of collagen-induced platelet aggregation, various approaches were taken using different models. We made transgenic mice with a PACAP overexpression in the megakaryocyte lineage. As for the patients, these mice presented with an increased bleeding time and showed a decreased sensitivity towards collagen-induced aggregation (
FIG. 4A ). In another set of experiments, the patient phenotype was reversed, i.e. the activity of PACAP was neutralized by addition of the PACAP antagonist PACAP(6-38). This recombinant peptide has a 10-100 times higher affinity for the VPAC1 receptor than PACAP(1-38) but seems not to activate adenylyl cyclase (Vaudry et al., (2000) cited supra). PACAP(6-38) enhanced the collagen-induced aggregation of normal human platelets in a dose-dependent manner (FIG. 4B ) and decreased basal cAMP levels (data not shown). The PACAP antagonist also induced a partial but consistent improvement of the collagen-induced platelet aggregation in the patient (FIG. 4B ). - The functional platelet aggregation inhibition test for a control person in the presence of PACAP (6-38) results in a Gs loss-of-function (
FIG. 4B ). The influence of PACAP(6-38) on the platelet aggregation test for patient VI:1 was not that pronounced, probably because his PACAP plasma levels were too high. - Functional platelet studies from patient VI:1 show that increased levels of PACAP(1-38) in plasma result in increased basal cAMP levels and a platelet hypofunction. The role of PACAP(1-38) in platelet function was also studied in mice by subcutaneous injection of polyclonal or monoclonal anti-PACAP antibodies.
- FVB mice were injected three times subcutaneously with 200 mg of an anti-PACAP or a control anti-b2-glycoprotein I polyclonal antibody or four times with 50 mg of an anti-PACAP (PP1A4) or an anti-RGS2 monoclonal antibody with an interval of 3 days between injections. At
day 14 after the first injection, whole blood from the inferior vena cava of mice anesthetized by intraperitoneal injection of 60 mg/kg sodium pentobarbital was drawn into 20 μg/mL hirudin. A platelet count was performed on the venous blood sample using the Cell Dyne 1300 (Abbott). Blood was centrifuged at 100 g for 10 min, allowing separation of PRP, and PPP was obtained by centrifugation of the remaining blood at 2,000 g for 10 min. PRP and PPP were pooled from 5 mice in each group. Platelet aggregation was measured as described above with the platelet count adjusted to 250×109 platelets/L. - The antibodies had a similar effect on platelet aggregation as the PACAP antagonist PACAP(6-38). Platelets incubated with anti-PACAP antibodies (10 μg/ml) show an enhanced response towards collagen stimulation (
FIG. 5 ). Moreover, when mice were functionally tested byplatelet aggregation 7 days after their last injection, mice treated with anti-PACAP antibodies show the opposite phenotype to that observed in patient VI:1. In contrast to the treatment with the aspecific antibody against β2-glycoprotein I, anti-PACAP-treated mice show a weaker response towards activation of the Gs pathway and have an enhanced response towards collagen stimulation (FIG. 5A , B). - Functional platelet studies on patient VI:1 show that increased levels of PACAP(1-38) result in increased basal platelet cAMP levels and platelet hypofunction. Since this patient also was thrombocytopenic, we have investigated whether elevated PACAP(1-38) would be associated with defective platelet formation. Platelets from this patient are smaller as the mean platelet volume (MPV) was 8.2 fL (normal MPV: 9-13 fL) and FACS analysis of his platelets showed a reduced expression of glycoprotein IX (
FIG. 5D ). Morphological examination of the bone marrow from the patient revealed a moderate to normal presence of the megakaryocyte lineage, indicative also of a normal proliferation. Electron microscopy of 2.5% glutaraldehyde fixed and routinely prepared ultrathin sections showed the presence of megakaryocyte progenitors but no mature megakaryocytes. The immature megakaryoblasts seemed to have reduced levels of rough endoplasmic reticulum cisternae and free ribosomes (FIG. 5E ). Clear demarcation membranes were not seen. - Specific granules as well as some dense core vesicles were obvious. Bone marrow from PACAP overexpressing and control mice was grown for 11 days in the presence of TPO, IL-6, IL-1b and SCF (Blair et al. (20022) Br. J. Haematol. 116:912-919.); FACS analysis showed a reduced expression of glycoprotein IIIa in megakaryocytes from the transgenic animals (
FIG. 5D ), indicative of a maturation defect. Transgenic mice present with a normal platelet count but their platelets have reduced levels of glycoprotein IIb/IIIa. - The role of PACAP(1-38) in thrombopoiesis was therefore further studied in control mice by subcutaneous injection of neutralizing polyclonal or monoclonal anti-PACAP antibodies. Mouse platelet-rich-plasma incubated with anti-PACAP antibodies in vitro (10 mg/ml) show an enhanced response towards collagen (data not shown), similar to the findings with the PACAP antagonist PACAP(6-38) using human platelets (
FIG. 4B ). Moreover, 7 days after the last injection, anti-PACAP antibody treated mice show an enhanced response towards collagen ex vivo (FIG. 5B ). Mice injected with the anti-PACAP polyclonal antibodies (n=5) furthermore have increased platelet numbers incomparison to the control group (n=5) (1194±237×109 plt/L versus 722±178×109 plt/L, p=0.01-unpaired T-test) 14 days after the first injection. This experiment was repeated determining platelet numbers at different time points (days FIG. 5F ). Mice injected with anti-PACAP polyclonal antibodies already showed increasedplatelet numbers 3 days after antibody injection. - The increased thrombocytopoiesis after pre-treatment with a polyclonal anti-PACAP antibody was studied under conditions of chemically suppressed bone marrow by the agent busulfan. This was done by subcutaneous injection of mice with either a polyclonal anti-PACAP or a control polyclonal antibody (at
days days 8 and 11). The platelet number was counted at different time points. Mice pretreated with the polyclonal anti-PACAP antibody recovered more rapidly from their thrombocytopenic condition than the mice injected with the control antibody (FIG. 8A , B). - The generation of monoclonal antibodies is exemplified in extenso for PACAP (1-38). The same methodology can be used for shorter versions of PACAP (n terminally or c terminally truncated). The same methodology can also be used for a full length PACAP receptor or for a fragment thereof. Preferred fragments of a PACAP receptor are the extracellular domains of these receptors.
- A recombinant human PACAP(1-38) fusion protein, consisting of the amino acids encoded by the PACAP(1-38) peptide coupled to Glutathione S-transferase (GST) was expressed in Escherichia coli and purified by affinity chromatography on immobilized glutathione (Amersham Biosciences). Recombinant human PACAP(1-38) is mixed with an equal amount of an adjuvant, and an obtained mixture is than subcutaneously administrated to Balb/c male mice (8 weeks old upon the start of immunization) in an amount corresponding to an amount of PACAP(1-38) of 100 μg per 1 mouse (priming immunization). After about 21 days, immunization can be performed by subcutaneous administration in the same manner as described above (booster immunization). After 19 days or 30 days from the booster, the mice can administrated through their tail veins with 200 μl of a preparation obtained by diluting human PACAP(1-38) with PBS (phosphate-buffered physiological saline) to have a concentration of 250 μg/ml (final immunization). Spleens have than to be excised from the mice after about 3 days from the final immunization, and they have to be separated into single cells. Subsequently, the spleen cells should be washed with a proper medium, e.g. DMEM medium. On the other hand, suitable mouse myeloma cells (e.g. Sp2/0-Ag14) have to be collected in the logarithmic growth phase, and to be washed with a proper medium, e.g. DMEM medium. The spleen cells and the mouse myeloma cells have to be sufficiently mixed in a plastic tube in a ratio of numbers of the cells of 10:1, followed by addition of 50% (w/v) polyethylene glycol (PEG e.g. of Boehringer Mannheim, average molecular weight: 4000) to perform cell fusion at 37° C. for 7 minutes. After removal of the supernatant solution (by means of centrifugation), the residue is added with HAT medium (DMEM medium containing 10% fetal bovine serum added with hypoxanthine, aminopterin, and thymidine). The residue has to be suspended so that a concentration of the spleen cells of about 5×106 cells/ml is obtained. This cell suspension can than be dispensed and poured into 96-well plastic plates so that one well contains about 100 μl of the suspension, followed by cultivation at 37° C. in 5% carbon dioxide. HAT medium has to be supplemented; for instance in an amount of 50 μl/well on 2nd and 5th days. After that, half volume of the medium can be exchanged every 3 or 4 days in conformity with proliferation of hybridomas.
- Screening and Cloning of Hybridomas: Hybridomas, which produce the monoclonal antibody of the present invention, have to be screened for. This has to be done by using, as an index, the inhibitory activity of the monoclonal antibody on the physiological activity possessed by PACAP. Hybridomas, which produced monoclonal antibodies exhibiting reactivity with PACAP's have then to be selected from the selected clones. The obtained hybridomas have then to be transferred to a suitable medium for instance HT medium which is the same as HAT medium except that aminopterin is removed from HAT medium, and cultured further. Cloning can be performed twice in accordance with the limiting dilution method by which stable hybridomas are obtainable.
- Production and Purification of Monoclonal Antibodies: 2.6,10,14-Tetramethylpentadecane (e.g. Pristane of Sigma, 0.5 ml) can be intraperitoneally injected into Balb/c female mice (6 to 8 weeks old from the birth). After 10 to 20 days, cells of clones can be (1×106 to 107 cells) suspended in PBS and intraperitoneally inoculated into the mice. After 7 to 10 days, the mice can be sacrificed and subjected to an abdominal operation, from which produced ascitic fluid can be collected. The ascitic fluid can be centrifuged to remove insoluble matters, and a supernatant was recovered and stored at −20° C. until purification Consequently, IgG can be purified from the ascitic fluid supernatant described above by using Hi-Trap Protein-A antibody purification kit (available from Pharmacia, Roosendaal, Netherlands). Namely, the ascitic fluid (2 ml) can be added with Solution A (1.5 M glycine, 3 M NaCl, pH 8.9, 8 ml), and filtrated with a filter for filtration having a pore size of 45 μm (Millipore). After that, an obtained filtrate can applied to a column (column volume: 1 ml) charged with Protein Sepharose HP (produced by Pharmacia) sufficiently equilibrated with Solution A, and the column has be washed with Solution A in an amount of 10-fold column volume. Subsequently, an IgG fraction can be eluted with Solution B (0.1 M glycine, pH 2.8) in an amount of 10-fold column volume. The eluted IgG fraction can be dialyzed against PBS. The monoclonal antibodies can be determined for their IgG subclasses by using the purified antibodies obtained in the foregoing, by means of a commercially available subclass-determining kit (trade name: Mono Ab-ID EIA Kit A, produced by Zymed). This method is based on the ELISA method. The Inhibitory Activities of Monoclonal Antibodies can be tested for their possible stimulatory effect on collagen-induced (0.35 μg/ml) platelet aggregation of human or mouse platelets. A similar approach may be used for the preparation of monoclonal antibodies specific to VIP or to PACAP receptor VPAC1 or VPAC2 or fragments thereof. Such antibodies can be applied for dosing activating or inhibitory PACAP mimetics by ELISA, for the purpose of monitoring PACAP (analogues) concentrations in the plasma of treated subjects. The VPAC1 have been cloned (Harmar et al. (1998) Pharmacol Rev. 50: 265-270). The human VPAC1 receptor DNA has been characterised from a HT29 human colonic adenocarcinoma cell line library. Human VPAC1 receptor comprises 457 amino acids (Sreedharan et al. (1993) Proc. Natl. Acad. Sci. USA 92: 2939-2943). The human VPAC1 receptor gene is located on region p22 of chromosome 3 (Sreedharan et al. (1995) Biochem Biophys Res Commun 193: 546-553). Cell lines, such Saccharomyces cerevisae, which are naturally devoid of VPAC1, can be transfected to produce such (Hansen MK (1999) Receptors Channels 6: 271-281). Vectors for expression of a PACAP receptor have been described in WO0107478. The method for preparation of a PACAP receptor protein has been disclosed in patent application US20020155533.
- Preparation of F(ab′)2 or monovalent Fab fragments: In order to prepare F(ab′)2 fragments, the monoclonal antibody can be dialyzed overnight against a 0.1 mol/L citrate buffer (pH 3.5). The antibody (200 parts) are then digested by incubation with pepsin (1 part) available from Sigma (Saint-Louis, Mo.) for 1 hour at 37° C. Digestion is consequently stopped by adding 1 volume of a 1 M Tris HCl buffer (pH 9) to 10 volumes of antibody. Monovalent Fab fragments can prepared by papain digestion as follows: a 1 volume of a 1M phosphate buffer (pH 7.3) is added to 10 volumes of the monoclonal antibody, then 1 volume papain (Sigma) is added to 25 volumes of the phosphate buffer containing monoclonal antibody, 10 mmol/l L-Cysteine HCl (Sigma) and 15 mmol/L ethylene diaminetetra-acetic acid (hereinafter referred to as EDTA). After incubation for 3 hours at 37″ C, digestion is stopped by adding a final concentration of 30 mmol/l freshly prepared iodoacetamide solution (Sigma), keeping the mixture in the dark at room temperature for 30 minutes. Both F(ab′)2 and Fab fragments can further be purified from contaminating intact IgG and Fc fragments using protein-A-Sepharose. The purified fragments can finally dialyzed against phosphate-buffered saline (herein after referred as PBS). Purity of the fragments can be determined by sodiumdodecylsulphate polyacrylamide gel electrophoresis and the protein concentration can be measured using the bicinchonicic acid Protein Assay Reagent A (Pierce, Rockford, Ill.).
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/550,605 US20100129372A1 (en) | 2003-01-16 | 2009-08-31 | Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0300934.7 | 2003-01-16 | ||
GB0300934A GB0300934D0 (en) | 2003-01-16 | 2003-01-16 | Haemostasis |
GB0310037.7 | 2003-04-03 | ||
GB0307667.6 | 2003-04-03 | ||
GB0307667A GB0307667D0 (en) | 2003-04-03 | 2003-04-03 | Haemostasis and thrombosis |
GB0310037A GB0310037D0 (en) | 2003-04-03 | 2003-04-03 | Haemostasis and thrombocytopoiesis |
US10/542,238 US7615219B2 (en) | 2003-01-16 | 2004-01-16 | Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia |
PCT/EP2004/001209 WO2004062684A2 (en) | 2003-01-16 | 2004-01-16 | Treatment of thrombocytopenia with inhibitors of pacap |
US12/550,605 US20100129372A1 (en) | 2003-01-16 | 2009-08-31 | Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/001209 Continuation WO2004062684A2 (en) | 2003-01-16 | 2004-01-16 | Treatment of thrombocytopenia with inhibitors of pacap |
US10/542,238 Continuation US7615219B2 (en) | 2003-01-16 | 2004-01-16 | Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100129372A1 true US20100129372A1 (en) | 2010-05-27 |
Family
ID=32718564
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/542,238 Expired - Fee Related US7615219B2 (en) | 2003-01-16 | 2004-01-16 | Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia |
US12/550,605 Abandoned US20100129372A1 (en) | 2003-01-16 | 2009-08-31 | Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/542,238 Expired - Fee Related US7615219B2 (en) | 2003-01-16 | 2004-01-16 | Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia |
Country Status (3)
Country | Link |
---|---|
US (2) | US7615219B2 (en) |
EP (1) | EP1583550A2 (en) |
WO (1) | WO2004062684A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016168768A3 (en) * | 2015-04-16 | 2016-12-01 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
WO2017181039A1 (en) * | 2016-04-15 | 2017-10-19 | Alder Biopharmaceuticals, Inc. | Humanized anti-pacap antibodies and uses thereof |
US9939449B2 (en) | 2011-02-01 | 2018-04-10 | The University Of Vermont And State Agricultural College | Diagnostic and therapeutic methods and products related to anxiety disorders |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1583550A2 (en) * | 2003-01-16 | 2005-10-12 | D. Collen Research Foundation vzw | Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia |
US20100196509A1 (en) | 2005-02-28 | 2010-08-05 | Jonathan Braun | Methods for Diagnosis and Treatment of Endometrial Cancer |
US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
EP2009026A1 (en) * | 2007-06-29 | 2008-12-31 | ThromboGenics N.V. | Anti-VPAC1 antibodies and their uses |
US20110229423A1 (en) * | 2008-07-18 | 2011-09-22 | Galderma Research & Development | Pacap signaling pathway modulators for treating inflammatory skin diseases having a neurogenic component, notably rosacea, and compositions comprised thereof |
EP2501409A4 (en) | 2009-11-20 | 2015-02-18 | Univ California | Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr) |
WO2011103599A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The Universith Of California | Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases |
EP3683237A1 (en) | 2013-03-15 | 2020-07-22 | Amgen Inc. | Human pac1 antibodies |
MX2017003247A (en) | 2014-09-15 | 2017-11-30 | Amgen Inc | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof. |
US10822408B2 (en) | 2015-12-15 | 2020-11-03 | Amgen Inc. | PACAP antibodies and uses thereof |
AR113022A1 (en) | 2017-09-29 | 2020-01-15 | Lilly Co Eli | ANTI-PACAP ANTIBODY |
JP7339262B2 (en) | 2018-01-12 | 2023-09-05 | アムジェン インコーポレイテッド | PAC1 antibody and uses thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2845210A (en) * | 1953-05-22 | 1958-07-29 | River Raisin Paper Company | Container for bulk package parts |
US3960312A (en) * | 1975-08-25 | 1976-06-01 | Hoerner Waldorf Corporation | Die cut container |
US4165031A (en) * | 1978-03-22 | 1979-08-21 | Westvaco Corporation | Short depth returnable bottle container |
US4403729A (en) * | 1981-07-20 | 1983-09-13 | Weyerhaeuser Company | File folder box |
US5273963A (en) * | 1991-03-29 | 1993-12-28 | The George Washington University | Compositions and methods for treating small cell and nonsmall cell lung cancers |
US5486472A (en) * | 1990-03-17 | 1996-01-23 | Takeda Chemical Industries, Ltd. | Monoclonal antibodies to PACAP |
US6242563B1 (en) * | 1998-07-20 | 2001-06-05 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Peptide analogues |
US20020182729A1 (en) * | 2001-01-11 | 2002-12-05 | Dicicco-Bloom Emanuel | Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo |
US7615219B2 (en) * | 2003-01-16 | 2009-11-10 | Life Sciences Research Partners Vzw | Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia |
US20100104530A1 (en) * | 2007-06-26 | 2010-04-29 | Kathleen Freson | Anti-vpac1 antibodies and their uses |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000005260A1 (en) | 1998-07-20 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Peptide analogues of pacap |
JP2003530297A (en) | 1998-10-16 | 2003-10-14 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Combination therapy using VIP antagonists |
SK5552002A3 (en) * | 1999-09-28 | 2003-05-02 | Bayer Ag | Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use |
-
2004
- 2004-01-16 EP EP04702708A patent/EP1583550A2/en not_active Withdrawn
- 2004-01-16 US US10/542,238 patent/US7615219B2/en not_active Expired - Fee Related
- 2004-01-16 WO PCT/EP2004/001209 patent/WO2004062684A2/en active Search and Examination
-
2009
- 2009-08-31 US US12/550,605 patent/US20100129372A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2845210A (en) * | 1953-05-22 | 1958-07-29 | River Raisin Paper Company | Container for bulk package parts |
US3960312A (en) * | 1975-08-25 | 1976-06-01 | Hoerner Waldorf Corporation | Die cut container |
US4165031A (en) * | 1978-03-22 | 1979-08-21 | Westvaco Corporation | Short depth returnable bottle container |
US4403729A (en) * | 1981-07-20 | 1983-09-13 | Weyerhaeuser Company | File folder box |
US5486472A (en) * | 1990-03-17 | 1996-01-23 | Takeda Chemical Industries, Ltd. | Monoclonal antibodies to PACAP |
US5273963A (en) * | 1991-03-29 | 1993-12-28 | The George Washington University | Compositions and methods for treating small cell and nonsmall cell lung cancers |
US6242563B1 (en) * | 1998-07-20 | 2001-06-05 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Peptide analogues |
US20020182729A1 (en) * | 2001-01-11 | 2002-12-05 | Dicicco-Bloom Emanuel | Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo |
US7615219B2 (en) * | 2003-01-16 | 2009-11-10 | Life Sciences Research Partners Vzw | Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia |
US20100104530A1 (en) * | 2007-06-26 | 2010-04-29 | Kathleen Freson | Anti-vpac1 antibodies and their uses |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9939449B2 (en) | 2011-02-01 | 2018-04-10 | The University Of Vermont And State Agricultural College | Diagnostic and therapeutic methods and products related to anxiety disorders |
US10228378B2 (en) | 2011-02-01 | 2019-03-12 | The University Of Vermont And State Agricultural College | Diagnostic and therapeutic methods and products related to anxiety disorders |
EP3283169A4 (en) * | 2015-04-16 | 2019-03-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
CN108055848A (en) * | 2015-04-16 | 2018-05-18 | 奥尔德生物制药公司 | Anti- PACAP antibody and application thereof |
US10844116B2 (en) | 2015-04-16 | 2020-11-24 | The University Of Iowa Research Foundation | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
US20160376363A1 (en) | 2015-04-16 | 2016-12-29 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
US10899834B2 (en) | 2015-04-16 | 2021-01-26 | H. Lundbeck A/S | Anti-PACAP antibodies |
CN108137677A (en) * | 2015-04-16 | 2018-06-08 | 奥尔德生物制药公司 | Anti- PACAP antibody and application thereof |
US11993648B2 (en) | 2015-04-16 | 2024-05-28 | H. Lundbeck A/S | Screening method for identifying anti-PACAP antibodies or antibody fragments suitable for use in treating or preventing PACAP-associated photophobia or light aversion |
KR102648281B1 (en) * | 2015-04-16 | 2024-03-14 | 하. 룬드벡 아크티에셀스카브 | Anti-PACAP antibodies and uses thereof |
EP3283517A4 (en) * | 2015-04-16 | 2019-03-06 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
EP3283168A4 (en) * | 2015-04-16 | 2019-03-06 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
EP3283516A4 (en) * | 2015-04-16 | 2019-03-06 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
US11254741B2 (en) | 2015-04-16 | 2022-02-22 | H. Lundbeck A/S | Anti-PACAP antibodies |
WO2016168768A3 (en) * | 2015-04-16 | 2016-12-01 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
US10981984B2 (en) | 2015-04-16 | 2021-04-20 | H. Lundbeck A/S | Methods of determining whether anti-PACAP antibodies inhibit PACAP-associated photophobia or light aversion |
KR20180002684A (en) * | 2015-04-16 | 2018-01-08 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | Anti-PACAP antibodies and uses thereof |
US10981985B2 (en) | 2015-04-16 | 2021-04-20 | H. Lundbeck A/S | Anti-PACAP antibodies |
WO2016168762A3 (en) * | 2015-04-16 | 2016-12-22 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
TWI721976B (en) * | 2015-04-16 | 2021-03-21 | 美商艾爾德生物製藥股份有限公司 | Anti-pacap antibodies and uses thereof |
TWI721975B (en) * | 2015-04-16 | 2021-03-21 | 美商艾爾德生物製藥股份有限公司 | Anti-pacap antibodies and uses thereof |
US10954285B2 (en) | 2016-04-15 | 2021-03-23 | H. Lundbeck A/S | Humanized anti-PACAP antibodies |
US10968268B2 (en) | 2016-04-15 | 2021-04-06 | H. Lundbeck A/S | Humanized anti-PACAP antibodies |
US10975135B2 (en) | 2016-04-15 | 2021-04-13 | H. Lundbeck A/S | Humanized anti-PACAP antibodies |
WO2017181039A1 (en) * | 2016-04-15 | 2017-10-19 | Alder Biopharmaceuticals, Inc. | Humanized anti-pacap antibodies and uses thereof |
US20190233498A1 (en) * | 2016-04-15 | 2019-08-01 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
US10913783B2 (en) | 2016-04-15 | 2021-02-09 | H. Lundbeck A/S | Humanized anti-PACAP antibodies and uses thereof |
US11352409B2 (en) * | 2016-04-15 | 2022-06-07 | H. Lundbeck A/S | Anti-PACAP antibodies and uses thereof |
US10202435B2 (en) | 2016-04-15 | 2019-02-12 | Alder Biopharmaceuticals, Inc. | Anti-PACAP antibodies and uses thereof |
US11938185B2 (en) | 2016-04-15 | 2024-03-26 | H. Lundbeck A/S | Treatment of headache, migraine and/or photophobia conditions using humanized anti-PACAP antibodies |
CN109311977A (en) * | 2016-04-15 | 2019-02-05 | 奥尔德生物制药公司 | Anti- PACAP antibody of humanization and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2004062684A3 (en) | 2005-01-06 |
EP1583550A2 (en) | 2005-10-12 |
WO2004062684A2 (en) | 2004-07-29 |
US20060062785A1 (en) | 2006-03-23 |
US7615219B2 (en) | 2009-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100129372A1 (en) | Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia | |
O'Dowd et al. | The cloning and chromosomal mapping of two novel human opioid-somatostatin-like receptor genes, GPR7 and GPR8, expressed in discrete areas of the brain | |
EP2322558B1 (en) | Antibodies directed against glycoprotein VI and uses thereof | |
US6245332B1 (en) | Modulation of systemic memory T cell trafficking | |
US20070048325A1 (en) | Combination therapies for inhibiting integrin-extracellular matrix interactions | |
Freson et al. | The pituitary adenylate cyclase–activating polypeptide is a physiological inhibitor of platelet activation | |
Marg et al. | Neurotractin, a novel neurite outgrowth-promoting Ig-like protein that interacts with CEPU-1 and LAMP | |
EP2313432B1 (en) | Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders | |
KR20040004509A (en) | Novel protein and process for producing the same | |
US20060025335A1 (en) | Netrin compositions and methods of using the same | |
JP2003534384A (en) | Neuroprotective peptide | |
JPH06506596A (en) | Interleukin-8 receptor and related molecules and methods | |
AU2672899A (en) | Protease-activated receptor 4 and uses thereof | |
US20050119198A1 (en) | Novel target to inhibit angiogenesis | |
EP1910828A2 (en) | Phosphospecific chemokine receptor antibodies | |
EP2218457B1 (en) | CD44v6 peptides as inhibitors of bacterial infections | |
EP1332761A1 (en) | Agonists of fibroblast growth factor receptors (FGFR) | |
US20050175609A1 (en) | Placental growth factor as a target for the treatment of osteoporosis | |
EP1578797A1 (en) | The transmembrane protein amigo and uses thereof | |
EP3649159B1 (en) | Fusion protein | |
Yu et al. | Identification of a novel CD40 ligand for targeted imaging of inflammatory plaques by phage display | |
JP4469180B2 (en) | Tenascin W composition and use thereof | |
EP3116526B1 (en) | Pharmaceutical compositions comprising april for use the treatment of multiple sclerosis, autoimmune encephalitis, neuromyelitis optica, alzheimer disease or parkinson disease | |
US7427488B2 (en) | Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same | |
JP4346540B2 (en) | Extravillous trophoblast cell-specific protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LIFE SCIENCES RESEARCH PARTNERS VZW, BELGIUM Free format text: CHANGE OF NAME;ASSIGNOR:D. COLLEN RESEARCH FOUNDATION VZW;REEL/FRAME:023172/0258 Effective date: 20070911 Owner name: D. COLLEN RESEARCH FOUNDATION VZW, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FRESON, KATHLEEN;VAN GEET, CHRIS;HOYLAERTS, MARC;REEL/FRAME:023170/0195 Effective date: 20051223 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |